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Monolayer functionalized ultra-small gold nanoparticles (AuNPs) provide a versatile 
platform for applications in cell research. Through rational design of surface ligands, the chemistry 
of AuNPs are precisely regulated at atomic level. In this dissertation, applications of AuNPs in cell 
modulation are discussed. The topics are split into two categories. In the first category, 
functionalized AuNPs are harnessed to generate a robust monolayer on cell culture surface for 
cell modulation. The proliferation and behavior of different types of cancer cells and normal cells 
are modulated by tuning the surface ligands of AuNPs. Fate decision of mesenchymal stem cells 
are also modulated using the same strategy. In the second category, AuNPs are assembled to 
nanoparticle stabilized capsules (NPSCs) for the delivery of a variety of proteins to cytosol of cells. 
Using this method, phenotype of cells are rapidly switched without genomic disturbance. In 
addition, subcellular localization of proteins are also controlled by the combination of subcellular 
localization signals and NPSC delivery platform. The first non-peptide synthetic nuclear 
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NANOMATERIALS FOR CELL MODULATION 
1.1 An overview of cell modulation 
Cell is the fundamental unit of structure and function in living organisms. Generally, cells 
are responsible for basic functions such as growth, metabolism and reproduction. Cells with 
similar functions form tissues and organs that are responsible for the vitality of higher organisms 
such as human beings. Dysfunction of cells is associated with numerous infectious1-3 and 
noncommunicable4-6 diseases. Therefore, cells are primary targets in multiple clinical applications, 
such as organ transplantation,7 tissue regeneration and engineering,8 wound healing9 and disease 
therapies.10   
Modulation of cells naturally occurs and has been broadly used in research and clinical 
applications. Literally, processes that modify cell genotype, phenotype, behavior, signaling and 
viability are categorized to cell modulation. Modulation of cells in nature associates with 
development,11 cell maturation,12 organ and tissue renewal13 and senescent cell clearance.14 For 
example, during the development of embryo, cells in blastocyst are modulated to different fates 
for further tissue and organ formation;15 in hematogenesis, hematopoietic stem cells are 
modulated by surrounding niches for the generation of different types of terminal blood cells;16 
old cells or abnormal cells are modulated to death by themselves, microenvironment or killer cells 
through the activation of apoptosis signals17 or the intracellular delivery of killing proteins such 
asgranzymes.18  
Cell modulation has been extensively investigated in research (Figure 1.1). As a basic 
biological technique, cell culture is a typical and one of the oldest example of in vitro cell 
modulation. Since the success of HeLa cell culture, numerous cell types have been isolated from 
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tissues and are eternally growing in laboratories and factories all over the world. To effectively 
culture cells, an appropriate environment and enough nutrient must be supplied. Additional 
supplements may also be required including chemical and biological compounds to induce the 
proliferation and maintain or change phenotypes of cells. Adapted from nature, different kinds of 
signaling proteins originated as in vivo cell modulators have been heavily harnessed,19, 20 such as 
epidermal growth factor, transforming growth factors and bone morphogenetic proteins, 
Cytokines and leukemia inhibitory factor. Chemical compounds including inhibitors, inducers and 
other types of regulators have been employed for phenotypical and behavioral modulations as 
well. Dexamethasone, a steroid medication, is an indispensable compound for osteoblast 
generation21 and immune cell modulation;22 CHIR99021, a GSK3α/β inhibitor, has been used for 
stem cell maintenance and differentiation;23 a cocktail of chemicals alone was reported to 















Another classical set of approaches is to deliver genes, mRNAs, siRNAs and proteins to 
cells to modify the genotype or phenotype of cells. Introduction or deletion of genes by virus,25 
plasmids26 and genomic editing proteins27 provides a powerful means to modify cell behaviors 
and functions, thus greatly facilitate the fundamental discovery and development of therapeutic 
methods. A representative example is the reprogramming of induced pluripotent stem cells from 
somatic cells. Yamanaka et al successfully induced fibroblasts to pluripotent stem cells by 
transfection of four genes with viral vectors in 2006.28 After that, numerous other delivery vectors 
have been thoroughly studied for reprogramming various types of cells.29  
 
In recent years, environment based controls have been an emerging technique for the 
modulation of cells, especially for the control of cell phenotype, behaviors and fate decision.30 To  
this end, different environmental controlling strategies have been developed.31 A straightforward 
way is to mimic the in vivo conditions using chemical or biological materials. For example, collagen 
and derivatives have been used to reconstruct the extracellular matrix for cell growth.32 Synthetic 
polymers have also been developed to simulate the extracellular matrix for better cell 
maintenance or modulations.33 More recently, organs have been decellularized with surfactants 
and repopulated with specific cell types for regeneration. Regenerated organs can be 
transplanted back to animals and regain functions.34 Without a doubt, cell modulation will play a 
major role for the clinical practice in the future for disease therapy and wound healing. 
1.2 Nanotechnology for cell modulation 
1.2.1 Nanotechnology 
In 1959, Late Nobel Laureate Richard Feynman raised nanotechnology in his revolutionary 
lecture “There's plenty of room at the bottom”.35 In the lecture, manipulating small-scale 
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molecules for large-scale benefits was discussed. Since then, nanotechnology, a discipline 
composed of science, technology and engineering manipulating at nanoscale, has attracted 
attentions from both research and industry sectors. Properties of nanostructured materials differ 
from their bulk counterparts. At nanoscale, materials bear reduced elastic modulus, decreased 
melting points, increased diffusion, enhanced solid solubility, lower thermal conductivity and 
novel optical property.36 Due to such difference, nanotechnology has been rapidly developing in 
multiple disciplines, including chemistry, biology, physics, materials science, and engineering. 
Nanotechnology covers a series of aspects including nanomaterials, a set of substances where at 
least one dimension is at nanoscale,37 and nanofabrication, a collection of techniques that 
generates reproducible patterns whose elements have sizes of 100nm or less in at least one 
dimension.38  
Nanotechnology has greatly broadened the application of materials in biological and 
clinical applications. Besides widely sold gold nanoparticle based pregnancy test strips, numerous 
nanomaterials and nanodevices have been commercialized or in clinical trials (Table 1.1). In 
addition, nanomaterials have been exploited as magnetic resonance imagining contrast agents39 
and optical/fluorescent imaging agents,40 as well as various disease detection sensors.41 
1.2.2 Nanotechnology for drug delivery 
Delivery of functional molecules to cells belongs to one category of cell modulation. 
Delivery of drugs alters cell viability and behavior, as well as induces cell death. Delivery of 
macromolecules, such as proteins, DNA and RNA, modifies the phenotype or genotype of cells. 
Due to their large surface to mass ratio, facile cellular internalization, nanomaterials especially 
nanoparticles are ideal vehicles for delivery of functional molecules to cells.42 Through 
nanomaterials based delivery vehicles, drugs target diseases with increased efficiencies.43 
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Amongst vast amount of nanovehicles, some have been commercialized for clinical uses, such as 
Doxil, a liposome based doxorubicin drug for cancer therapy.44 More examples can be found in 
Table 1.1. Successes in commercialization of these drugs greatly inspired the development of this 
area. A number of new nanovehicles for drug delivery is  created every year,45 including 
nanoparticles, polymers, dendrimers and liposomes and lipids. 
Table 1.1. Examples of commercialized nanoscale systems for disease therapies46, 47 
Drug 
product 
Active ingredient Indications 
Doxil 
(Caelyx) 
Pegylated doxorubicin Ovarian/breast cancer 
Abraxane Albumin-bound Paclitaxel 
nanospheres 
Various cancers 
Nab paclitaxel in combination 
with gemcitabine 
Metastatic pancreatic cancer 





HIV-related Kaposi sarcoma 
DepoCyt Liposomal  Cytarabine Lymphomatous meningitis 
Oncaspar PEGasparaginase Acute Lymphocytic Leukemia 
Marqibo Vincristine Philadelphia chromosome-negative 
lymphoblastic leukemia 
Genexal-PM Paclitaxel-loaded polymeric 
micelle 
Breast cancer/small cell lung cancer 
Ontak Diphtheria toxin Cutaneous T-cell 
ThermoDox Heat-activated liposomal 
encapsulation of doxorubicin 
Breast cancer, primary liver cancer 
Rexin-G Targeting protein tagged 
phospholipid/microRNA-122 
Sarcoma, osteosarcoma, pancreatic 
cancer, and other solid tumor 
Resovist  Iron oxide nanoparticles coated 
with carboxydextran 
Liver/spleen lesion imaging 
Feridex Iron oxide nanoparticles coated 
with dextran 
Liver/spleen lesion imaging 
Endorem Iron oxide nanoparticles coated 
with dextran 




1.2.3 Nanotechnology for External Cell Modulation 
Modulating the proliferation and function of cells through external stimulation have been 
achieved using nanotechnology as well. Nanomaterials show high potential for the modulation of 
cells. Recently, Mooney et al reported that elasticity of nanoporous hydrogel controls 
transplanted-stem-cell-mediated bone formation.48 Ding et al discovered that by spatial 
organization of cell-adhesive ligands on nanoparticles as well as matrix stiffness direct the fate 
decision of stem cells.49 In another research conducted by Di Carlo et al, nanomagnets was found 
to engineer the polarity of neuron, yielding new insights into mechanotransduction in neural 
networks.50 Through nanopartterning, shape,51 growth52 and differentiation53 of cells were 
modulated. Although techniques or materials of nanotechnology employed for cell research vary, 
they all take advantage of the interactions between cells and support materials at nanoscale. 
Through ratinal design, physical, chemical and biological properties of materials can be harnessed 
for precise modulation of cells for both research and applications. 
1.3 Gold nanoparticles 
The use of gold nanoparticles (AuNPs) can be backtracked to ancient Egypt and Roman 
times.54 AuNPs bear advantageous physical, chemical and biological properties that have been 
adopted in immense applications.55 AuNPs are optically differed from bulk gold. The surface 
plasmon resonance of AuNPs leads to strong electromagnetic fields on the particle surface and 
consequently enhances all the radiative properties of both light absorption and scattering.56 
AuNPs are relatively inert in biological environment, making them compatible for biomedical 
applications.57  In addition, size, shape, and surface properties of AuNPs can be facilely modulated 




1.3.1 Synthesis of gold nanoparticles 
In general, the synthesis of AuNPs includes the nucleation of AuNP cores and stabilization 
of AuNPs with a shell to prevent aggregation. AuNPs can be synthesized in both aqueous solution 
and organic solvents. For the synthesis in aqueous solution, stabilizer are chosen from small 
molecules, such as citrate59 and polyphenols,60 to macromolecules,61 including polymers, proteins 
and DNA. However, direct synthesis of AuNPs in aqueous solution has intrinsic drawbacks. 
Particularly, once AuNPs are wrapped with stabilizers, they are difficult to be further 
functionalized, limiting their further applications. 
Phase transfer is an alternative strategy for the synthesis of AuNPs with the ease of 
preparation, purification and further functionalization. Phase transfer technique includes two 
basic steps, nucleation and stabilization (Figure 1.2). Apart from aqueous synthesis, these two 
steps occur in organic solvents. For example, in the classical Brust–Schiffrin method,62 
tetraoctylammonium bromide (TOAB) was employed to transfer hydrogen tetrachloroaurate 
(HAuCl4) from aqueous phase to the organic phase and then sodium borohydride (NaBH4) was 
used to reduce the gold salt to AuNPs. Immediately after the nucleation, the surfaces of AuNPs 
were protected with a monolayer of thiols for stabilization. This monolayer can be readily 
displaced with functionalized ligands for further applications (Figure 1.2). 
 
Figure 1.2. Preparation of monolayer-protected AuNPs using the Brust–Schiffrin reaction, and 




1.3.2 Functionalization of monolayer protected gold nanoparticles 
AuNPs synthesized with phase transfer method are covered with labile capping agents on 
the surface, such as thiols. These agents, however, can be displaced by rationally designed 
functional ligands thereafter. Since 1996, Murray et al have studied the ligand substitution, or 
place exchange, on AuNP surface in a series of research and paved the way for precise 
functionalization of ultra-small AuNPs.64, 65 
Place exchange is a process that substitutes anchored primary ligands on AuNP surface 
with secondary free ligands. In the pioneer research done by Murray et al,65 two important 
principles were drawn: (1) more polar ligands displace less polar ligands; (2) Ligands with longer 
chain displace ligands with shorter chain. Based on these principles, Rotello et al further 
developed a series of ligands for place exchange that both well protects and precisely 
functionalizes AuNPs. A representative structure of such ligand is shown in Figure 1.3. This type 
of ligand is composed of a thiol terminal for interaction with the AuNP core, a hydrophobic chain 
for stability, an oligo(ethylene glycol) layer for biocompatibility, and terminal residues for 
functions.66 By tuning the terminal residues, the function of AuNPs can be specified. This approach 
standardized the preparation of functionalized AuNPs with tunable functions, thus opening up a 
new avenue for the use of AuNPs in different scenarios. 
 




1.3.3 Biomedical applications of gold nanoparticles 
AuNP is one of the earliest commercialized nanomaterials for biomedical applications. In 
recent years, a number of new applications of AuNPs have been developed, such as sensors, 
heating sources and delivery vehicles.67 As pioneers in this field, Rotello et al applied monolayer 
protected AuNPs to numerous applications by taking advantage of the interactions between 
AuNPs and biological substrates (Figure 1.4). Interactions between AuNPs and biological 
molecules have been thoroughly analyzed.68-72 AuNPs have also been utilized as a versatile sensing 
probe for the detection of different kinds of analytes, such as proteins,66 bacteria73 and cells.74 In 
another series of research, AuNPs were exploited as carriers for intracellular delivery of various 
molecules, such as drugs,75 proteins76 and DNA.77 By designing terminal residue of surface ligand, 
interactions of AuNPs with delivery payloads are readily modulated. Through cell uptake, various 
payloads have been successfully delivered to cells for specific functions. Decorating the surface of 
AuNPs with zwitterion ligands further modulates cell uptake, thus potentially affecting delivery 













1.4 Nanoparticle stabilized capsule 
In 1907, S. U. Pickering described an emulsion type that is consist of a hydrophobic core 
and a shell of solid particles adsorbed onto the interface between two phases (Figure 1.5). In 
Pickering emulsion system, the oil droplet is stabilized by a reduction of the bare oil-water 
interface by adsorption of solid particles wetted by both water and oil.80, 81 This old system is 
reviving recently due to its unique structure with the three interfacial interactions. For example, 
in 2002, Dinsmore et al developed a colloidosome system based on Pickering emulsion.82 
Microencapsulation by colloidosome enables controlled release of active compounds in various 
industrial and research sectors including medicine, food, home and personal care products, 
agrochemicals and cosmetics.83 This technique allows the delivery of a range of actives such as 
drugs, pesticides and fragrances for specific functions. 
 
Figure 1.5. Formation of Pickering emulsion. 
 
Traditionally, Pickering emulsion based systems are in microscale, limiting their 
applications for biomedical use. In 2010, Rotello et al developed a nanostructure based on 
Pickering emulsion, namely nanoparticle stabilized capsule (NPSC) that is composed of an oil core 
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and a nanoparticle shell (Figure 1.6).84 Through rational design of the nanoparticle surface, this 
structure maintains a nanometer size and is capable of delivering drugs and macromolecules into 
cells in a rapid diffusion fashion. 
 
Figure 1.6. Fabrication of stable nanoscale NPSCs.84 
1.4.1 Theoretical base of nanoparticle stabilized capsule (NPSC) 
There are three different interfaces in the Pickering emulsion, including solid 
particle/water, solid particle/oil and oil/water interfaces. The stabilization of Pickering emulsion 
can be described using the following Pieranski Equation:85 
∆𝐸 =  −
𝜋𝑟2
𝛾𝑜/𝑤
[𝛾𝑜/𝑤 − (𝛾𝑝/𝑤  −  𝛾𝑝/𝑜)] 
Where r is the effective radius of the solid particle, γo/w is the surface tension at oil/water 
interface, γp/w is the surface tension at solid particle/water interface and γp/o is the surface tension 
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at solid particle/oil interface. Clearly, change of interfacial energy is related to both the effective 
radius of the solid particle and the surface tensions of the above three interfaces. 
A major challenge to reduce the size of Pickering emulsion is the use of ultra-small 
nanoparticles as the emulsifier. According to the equation, it is difficult to maintain the NPSC 
structure if the size of the nanoparticle is too small. To overcome this problem, other interactions 
must be introduced into the NPSC system. By designing the surface ligand, the interaction 
between the oil core of the capsule with the nanoparticle that constitute the shell to access 
nanoscale assemblies was engineered. The NPSC structure was therefore stabilized through 
lateral particle-particle interactions and particle-protein interactions.84 This development has 
been proven as a direct technique for the formation of NPSCs featuring diameters around 100 nm 
that are stable in both buffer and cell culture medium.  
1.4.2 Applications of NPSCs 
The NPSC system has been successfully used in intracellular delivery of a variety of 
molecules. As a demonstration, Nile Red, a hydrophobic fluorescent dye, was rapidly delivered to 
cytosol of HeLa cells. Mechanism study revealed that the payload was transferred through 
membrane fusion from the NPSC to the cell without endocytosis. Delivery of paclitaxel to cells 
indicated that the release of therapeutic drugs from the NPSC is efficient.84 
Following this research, NPSCs were investigated for the delivery of macromolecules. In 
2013, proteins were delivered into cytosol of cells without sequestration in endosomes.86 In 2014, 
NPSCs through a set of orthogonal supramolecular interactions were generated for the co-
delivery of hydrophobic endosome-disrupting agents and fluorescent proteins to cells, thereby 
creating a system featuring stimuli-responsive release of a payload into the cytosol with 
fluorescence monitoring.87 In 2015, siRNA/NPSC nanocomplex was developed for efficient 
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cytosolic delivery of siRNA.88 Using this structure, siRNA was rapidly delivered into the cytosol 
through membrane fusion and 90% knockdown was observed. Co-delivery of anti-cancer drug and 
proteins for apoptosis was achieved using NPSCs as well.89 Higher cytotoxicity than either of the 
single agent was shown, with synergistic action established using combination index values. This 
NPSC platform has also been used for efficient eradication of bacterial biofilms while promoting 
fibroblast proliferation in a mixed bacteria/mammalian cell system,90 making it promising for 
wound healing applications. 
1.5 Dissertation overview 
Monolayer functionalized ultra-small AuNPs provide a versatile platform for applications 
in cell research. Through rational design of surface ligands, the chemistry of AuNPs are precisely 
regulated at atomic level. In this dissertation, applications of AuNPs in cell modulation are split 
into two categories (Figure 1.7). In the first category, functionalized AuNPs are harnessed to 
generate a robust monolayer on cell culture surface, thus modulating cell viability, behavior and 
fate decision. In the second category, AuNPs are assembled to NPSCs for the delivery of a variety 
of proteins to cytosol of cells. Using this method, phenotype of cells are rapidly switched without 
genomic disturbance. In addition, subcellular localization of proteins are also controlled by the 
combination of subcellular localization signals and NPSC delivery platform. The first non-peptide 




Figure 1.7. External and internal modulation of cells using functionalized nanoparticles. 
 
In Chapter 2, a robust monolayer of nanoparticles formed via dip-coating of cell culture 
plates has been developed. The coating is robust under cell culture conditions, and a negligible 
amount of AuNPs can be taken up by cells. Cell behaviors, such as morphologenesis, adhesion and 
proliferation, can be regulated through extracellular stimulation by the AuNP coating. The 
properties of the AuNP coated surfaces can be precisely tuned to regulate the cell behaviors and 
to selectively support cell growth. 
In Chapter 3, a defined chemical environment for stem cells has been prepared through 
dip-coating functionalized gold nanoparticles (AuNPs) onto cell culture plates. Modulation of 
mesenchymal stem cell (MSC) proliferation and differentiation has been achieved by precisely 
controlling the chemical structures of surface ligands on AuNPs. This generalized strategy opens 
up a facile way to adjust chemical clues for the modulation of stem cell growth. 
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In Chapter 4, a general strategy for direct delivery of functional proteins to the cytosol 
using nanoparticle-stabilized capsules (NPSCs) has been discussed. Intracellular protein delivery 
is an important tool for both therapeutic and fundamental applications. Effective protein delivery 
faces two major challenges: efficient cellular uptake and avoiding endosomal sequestration. 
NPSCs developed in this chapter were formed and stabilized via supramolecular interactions 
between the nanoparticle, the protein cargo, and the fatty acid capsule interior. The NPSCs were 
~130 nm in diameter and featured low toxicity and excellent stability in serum. The effectiveness 
of these NPSCs as therapeutic protein carriers was demonstrated through the delivery of fully 
functional caspase-3 to HeLa cells with concomitant apoptosis. Analogous delivery of green 
fluorescent protein (GFP) confirmed cytosolic delivery as well as intracellular targeting of the 
delivered protein, demonstrating the utility of the system for both therapeutic and imaging 
applications. 
In Chapter 5, a method for quantitative monitoring of subcellular protein trafficking using 
NPSCs for protein delivery has been described. This method has provided rapid delivery of the 
protein into the cytosol, eliminating complications from protein homeostasis processes observed 
with cellularly expressed proteins. After delivery, nuclear protein trafficking was followed by real 
time microscopic imaging. Quantitative analyses of the accumulation percentage and the import 
dynamics of the nuclear protein trafficking, demonstrated the utility of this method for studying 
intracellular trafficking systems. 
In Chapter 6, the first non-peptide moiety that recruits intracellular transporting 
machineries for nuclear targeting has been discussed. In nature, a limited set of signaling peptides 
have been used to direct intracellular localization. Proteins synthetically modified with an 
aromatic boronic acid motif were effectively directed to the nucleus after cytosolic delivery using 
a nanoparticle-stabilized capsule system. Mechanistic studies revealed that active transport to 
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the nucleus occurd through the interaction between boronic acid and importin α/β, while the 
aromatic ring synergistically enhanced nuclear accumulation. Proteins too large to passively 
diffuse through nuclear pores were imported into the nucleus after being tagged with this 
aromatic boronic acid motif, further confirming an active transport mechanism. This purely 
synthetic methodology is a promising alternative strategy for directing subcellular localization for 
therapeutic and fundamental applications. 
In Chapter 7, an alternative NPSC system with simplified ligand structure has been 
developed for efficient delivery of proteins with large size into cytosol. Through weak interactions, 
proteins with high molecular weight were effectively delivered into cytosol without endosomal 
sequestration and maintained their natural structures and functions after delivery. This platform 
opens up new opportunities for efficient intracellular delivery of large proteins. 
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RAPID COATING OF SURFACES WITH FUNCTIONALIZED NANOPARTICLES FOR REGULATION OF 
CELL BEHAVIOR 
2.1. Introduction 
Material properties such as surface morphology,1 chemistry,2, 3 hydrophobicity,4, 5 and 
elasticity6, 7 can be used to regulate cell growth. With proper surface modification, cells can grow 
on materials otherwise biologically incompatible including plastics and inorganic platforms, such 
as polyester, polycaprolactone, polyetheretherketone, alumina and calcium phosphate.8-11 These 
modified surfaces have been used for in vitro cell culture, 12 tissue regeneration and organ 
rebuilding.13-15 Selectivity of cell proliferation on surfaces is an additional requirement for multiple 
applications, including wound healing,16 tissue repair,17 cell residence and development, as well 
as differentiation.18, 19 The capability of such surfaces to dictate cellular fate can be obtained by 
precisely defining surface components and structures. For example, RGD peptide has been used 
to selectively stimulate specific cell growth.20 Topography has also been harnessed to selectively 
trigger cell fate decisions.21  
Specifically tailoring surfaces to support growth of specific cell types is challenging, 
particularly in the context of processes amenable to manufacturing.22 While cells respond to their 
supporting microenvironment,23 developing a general strategy for precisely tuning the surface to 
optimize biocompatibility of specific cell type is currently unfeasible. Challenges for development 
include identifying appropriate surfaces, while manufacturing is complicated by the use of 
complex coating processes such as layer-by-layer deposition24, 25 and nanopatterning26 that are 
costly and time consuming and therefore challenging to implement for large-scale production.  
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Herein, we describe a rapid and scalable strategy to deposit a monolayer of functionalized 
gold nanoparticles (AuNPs) onto commercial polystyrene cell-culture plates. By tuning the 
terminal group of the ligand, the properties of AuNPs and hence the resulting surface can be 
precisely modulated to regulate cellular behavior. This control of surface functionality yields 
surfaces that show cell type selectivity in cell viability.   
2.2. Methods 
2.2.1. Syntheses of Ligands and AuNPs.  
The syntheses of most ligands have been reported elsewhere27-31 except T-Phe and T-
Adman ligands.  
2.2.2. Synthesis of T-Phe ligand 
The synthesis of T-Phe ligand was similar to that of T-Arg ligand. Briefly, trityl protected 
amine (Trt-C11-TEG-NH2) was firstly coupled with Boc-Phe-OH through EDC coupling. Then the 
resulting protected T-Phe was cleaved by trifluoroacetic acid (TFA) in the presence of 
triisopropylsilane (TIPS). T-Phe ligand was purified by washing the crude product with hexane and 
diethylether for three times, respectively. 1H NMR (400MHz, CDCl3, δ): 7.35-7.31 (5H, m, Ar), 5.32 
(1H, s, -NH-), 4.12-4.08 (1H, m, -CH-), 3.76-3.28 (19H, -OCH2-, CH2Ar), 3.08-3.02 (1H, s, -CH2Ar), 
2.53 (2H, q, J = 7.5 Hz, -SCH2-), 1.65-1.54 (4H, m, -CH2-), 1.41-1.27 (14H, m, -CH2-). MS (ESI, m/z): 
M+ calcd for C28H50N2O5S, 526.3; found, 526.5. 
2.2.3. Synthesis of T-Adman ligand 
The synthesis of T-Adman ligand also followed the previous published method. Briefly, 
trityl protected methanesulphonate (Trt-C11-TEG-MS) was reacted with 
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dimethyladamantaneamine in mixed solution of dichloromethane (DCM) and ethanol (1:3, v/v) at 
40 °C for 72 h. The product was then washed by hexane and hexane/DCM mixture (10:1, v/v) for 
five times, respectively. After that, T-Adman ligand was obtained by cleaving the washed product 
using TFA and TIPS followed by hexanes washing for three times. 1H NMR (400MHz, CDCl3, δ): 3.97 
(br, 2H, -OCH2-(CH2N)-), 3.74-3.58 (m, 14H, -CH2O- + -CH2N-), 3.46 (t, 2H, -CH2O-), 3.07 (s, 6H, -
(CH3)2N-), 2.78 (s, 3H, CH3SO-3-), 2.58 (q, 2H, -CH2S-), 2.36-2.12 (br, 9H, HAdamantane), 1.92-1.70 
(br, 6H, HAdamantane),  1.51-1.12 (m, 18H, -(SCH2)CH2 + -CH2(CH2O)- + SH + -CH2-). MS (ESI, m/z): 
M+ calcd for C31H60NO4S, 542.4; found, 542.5. 
2.2.4. Syntheses of Functionalized AuNPs 
The syntheses of functionalized AuNPs were accomplished by place exchange in the 
presence of purified ligands as described before.32 
2.2.5. AuNP Coating 
AuNPs were dissolved in MilliQ water at a concentration of 100 nM prior to coating. Then 
500 µL of AuNP solution were incubated in one well of a 24-well plate at 37 °C for 3 h (125 µL for 
96-well plate). Excess AuNPs were washed away with water three times followed by complete 
drying at 37 °C. 
2.2.6. Characterizations 
For both AFM and XPS characterization, the bottom of the plate coated by AuNPs was 
carefully removed. AFM imaging was performed on a DI Dimension-3100 AFM. Both height and 
phase images were collected. The average roughness of the determined sample area was 
calculated by Gwyddion, a freeware with the agreement of GNU General Public License. XPS 
 
23 
analysis was performed on a Physical Electronics Quantum 2000 spectrometer using a 
monochromatic Al Kα excitation at a spot size of 10 mm with pass energy of 46.95 eV at take-off 
angles of 15°, 45°, and 75°. For stability testing, the TTMA AuNP coating process was performed 
on a 96-well plate with or without plasma treatment. After washing with PBS three times, the 
surface was incubated with DMEM media containing 10% serum at 37 °C for 24 h, followed by 
treatment with trypsin for 5 min. AuNPs left on the plates were dissolved by using aqua regia for 
inductively coupled plasma mass spectrometry detection. 
2.2.7. Cell culture 
Cells were cultured in a humidified atmosphere (5% CO2) at 37 °C, and grown  in 
Dulbecco’s Modified Eagle’s Medium (DMEM, low glucose) supplemented with 10% fetal bovine 
serum (FBS) and 1% antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). To culture cells 
on the plates, 30,000 or 7,500 cells were plated on 24- or 96-well plates for a desired time (80 
min, 24 h or one week), respectively.   
2.2.8. Cell viability assay 
7,500 cells were cultured in a 96-well plate for 24 h with or without AuNP coating. Cells 
were then incubated with 200 μL DMEM containing 10% Alamar Blue. Cells growing in untreated 
wells were set as “Blank” group. The “Untreated” group was set by adding the same volume of 
the Alamar Blue media into the untreated wells without cells. After 3 h incubation, the 
fluorescence intensity (FI) of reduced Alamar Blue at 590 nm from each well was recorded with 
an excitation wavelength of 535 nm. By defining the cell viability of Blank as 100%, the viabilities 
of cells growing on AuNP coated wells were calculated using the following equation: 






Where FIBlank is the average fluorescence intensity of “Blank” group and FIuntreated is the 
average fluorescence intensity of “Untreated” group. 
2.3 Results and Discussion 
The first step for our modulation strategy is the "painting" of the surfaces using AuNPs. 
For our studies, AuNPs with 2 nm cores were functionalized with a variety of surface ligands. These 
ligands were designed to prevent protein fouling, maximizing the role of the particle in dictating 
cellular interactions.33 In our previous approach to NP-mediated surface modification, AuNPs with 
defined ligands were immobilized onto surfaces through chemical crosslinking.34 However, this 
method requires extra steps. In addition, the crosslinking reagents are cytotoxic and the residual 
after the reaction cannot be completely removed. In the current approach particles were 
deposited through simple dip coating of the particles onto commercial plasma-oxidized 
polystyrene cell-culture plates in an aqueous solution. (Figure 2.1a). Interactions between the 
plate and the AuNPs provided irreversible particle deposition (vide infra). The process was also 
self-passivating: after formation of an AuNP monolayer, no further deposition onto the surface 




Figure 2.1. Preparation and characterization of TTMA AuNP layer on the polystyrene-plate 
surface. a) Schematic representation of the strategy to generate a AuNP monolayer on the cell-
culture plate. b) Angle-resolved XPS detection of the polystyrene-plate surface with the AuNP 
layer. Relative atomic concentrations of C, N, O and Au are listed in the table. c) AuNPs attached 
to the plate with or without plasma treatment under cell-culture conditions. Each bar represents 
the amount of gold left in one well of a 96-well plate. The error bars represent the standard 
deviation of three measurements.  
 
A TTMA AuNP layer (see Figure 2.1a) was generated to characterize the AuNP-modified 
surfaces. The AuNP layer was formed by dipping a plasma-treated polystyrene culture plate 
surface into 100 nM aqueous solution of TTMA AuNPs. No significant differences in surface 
morphology and roughness between untreated and TTMA AuNP coated surfaces were observed 
(Figure 2.2) as detected by Atomic Force Microscopy (AFM). The AuNP layer on the template was 
then characterized by depth profiling using angle-resolved X-ray photoelectron spectroscopy 
(XPS).35 As shown in Figure 2.1b, there was a strong angular dependence of the Au peak and other 
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peaks associated with the AuNP signal. Particularly, the C/Au ratio increased from 45 (15°) to 91 
(75°) with increasing take-off angle. This angle-dependent increase coupled with the shake-up 
peak from the π-π interaction of polystyrene observed at 75° (inset of Figure 2.1b), confirms the 
detection of the polystyrene substrate. Considering the detection depth of XPS is ca. 5 nm,36 the 
thickness of the AuNP layer can be estimated to be less than 5 nm, consistent with a monolayer 
of particles.  
 
Figure 2.2. Characterizations of cell culture plate surface after TTMA AuNP coating. Untreated 
surface and surface treated with water without AuNPs were used as controls.  a) AFM images 
and related roughness measurements. b) Mean roughness values with triplicate determinations. 
 
The TTMA AuNP film was robust under cell-culture conditions: after washing with 
phosphate buffered saline (PBS) three times, the surface was incubated with Dulbecco's Modified 
Eagle Medium (DMEM) containing 10% serum at 37 °C for 24 h, followed by treatment with trypsin 
for 5 min. After this treatment, the loss of the AuNPs from the surface was negligible, as 
determined by inductively-coupled plasma mass spectrometry (ICP-MS) (Figure 2.1c). Even after 
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one week of culture replacing the media every other day, minimal AuNP uptake was detected, 
while a substantial amount of AuNPs (86.7%) remained in the plate (Figure 2.3). In contrast, 
without plasma treatment, TTMA AuNPs were easily washed away indicating that plasma 
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Figure 2.3. AuNPs amount taken up by cells and left on the cell culture plate surface after one 
week culture of HepG2 cells (started at 30,000 cells/well). The cell culture media were replaced 
every other day. 
 
Preliminary insight into the interaction of particle-modified surfaces and cells was 
obtained using surfaces coated with TTMA AuNPs. HepG2 cells were grown in the cell-culture 
plates with or without a TTMA AuNP coating. After 80 min incubation, cells cultured on the TTMA 
AuNP treated surface have already adhered and filopodia started to form. In contrast, few cells 
attached to the plate surface without AuNP layer at the same time point (Figure 2.4). After 24 h 
incubation, cells cultured on the TTMA AuNP treated surface exhibit distinctly different 
morphologies, with TTMA-treated surfaces encouraging cell spreading relative to the untreated 
control (Figure 2.5 and Figure 2.6). Staining with phallotoxin to specifically target F-actin 
demonstrates that cells grown on the AuNP surface have more filopodia than those grown on a 
plasma-treated surface (Figure 2.6c-d), indicative of enhanced adhesion.37, 38 Taken together, 
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these results reveal that TTMA AuNP monolayers can be successfully used to enhance the 
adhesion of cells. It is notable that ICP-MS indicated no loss of AuNPs from the polystyrene surface 
(Figure 2.6e), despite the fact that positively charged nanoparticles are known to be readily taken 
up by cells.39 Substitution of the AuNP for a TTMA CdSe quantum dot (core diameter ≈ 3 nm) also 
showed a stimulatory effect on cell morphogenesis that resembled that of the TTMA AuNPs 
(Figure 2.7). Thus it is clear that it is the surface ligand, rather than the core of the nanoparticle, 
that plays an important role in regulating the cell behavior. 
 
Figure 2.4. Attachment of HepG2 cells after 80 min incubation on cell culture plates a) without 







Figure 2.5. Optical images of HepG2 cell grown on a) plasma-treated plate and b) TTMA AuNP 





Figure 2.6. HepG2 cell culture for 24 h on plates with and without the TTMA AuNP layer. a) 
Optical image of HepG2 cell grown on a plasma-treated plate. b) Optical image of HepG2 cell 
grown on a TTMA AuNP monolayer. c) Fluorescent image of Figure 2.6a. F-actin was stained by 
Oregon Green labeled phallotoxin, and the nuclei were stained by Hoechst 33342. d) 
Fluorescent image of Figure 2.6b. The staining conditions were the same as in Figure 2.6c. The 
arrow indicates filopodia of the cell. e) Cell-uptake test of TTMA AuNP monolayer. The cells 
were cultured on the TTMA AuNP monolayer in a 24-well plate for 24 h. A 24-well plate coated 





Figure 2.7. HepG2 cells growing on TTMA CdSe quantum dots coated surface for 24 h showed 
similar morphology as those growing on TTMA AuNP coated surface. Bar: 100 µm 
 
 
Variation of surface ligands on AuNPs can be used to control surface properties,40  
providing a potential tool to regulate cellular behavior. To test this hypothesis, the effects of AuNP 
coatings on the viability on four kinds of cells from different organs was determined, namely 
HepG2 (human liver), HeLa (human cervix), MCF7 (human breast), and 3T3 (murine fibroblast). To 
perform this study, 26 kinds of functionalized AuNPs were screened, with different types of 
ligands of varying hydrophobic, stereoelectronic, constitutional, and aromatic characteristics 




Figure 2.8. Cell viability assay for 26 different AuNP coatings (morphology changes of HepG2 cell 
were shown in Figure 2.9). a) A heat map of cell viability influenced by different AuNP coatings. 
b) Structures of ligands on the AuNPs. ‘Blank’ represents the cell viability on plasma-treated 
surface without any pretreatment, and ‘Water’ represents the cell viability on the surface 






Figure 2.9. Morphologies of HepG2 cell in the presence of AuNPs listed in Figure 2.8. Bar: 100 
µm 
 
Cell viability was determined using an Alamar blue assay (Figure 2.8). The matrix of the 
26 nanoparticles against the four cell lines indicated that different AuNPs had marked and 
selective effects on the viability of the different cell lines. It is evident that these cationic NPs 
(TTMA) dramatically increased the viability of HepG2 cells and to a lesser extent MCF7 cells, while 
having minimal effect on HeLa and 3T3 cells. These differences among cell types may be due to 
the sensitivity of the cells responding to the environment. However, this tendency was not 
universal and certain cationic nanoparticles promoted the growth of specific cell lines while 
inhibiting others, for example aromatic functionalities (T-Ph and T-Benzyl) that significantly 
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boosted the viability of HepG2 comparative to the other the cell lines. A similar case was observed 
when the hydrophobicity of the ligand increases. While the more hydrophilic NPs (TTMA to T-C6, 
and T-C2-NH2 to T-C3-OH2) boosted the viability of both HepG2 and MCF7, the more hydrophobic 
NPs (T-C14 to T-dbC6) increased the viability only for HepG2, as MCF7 is apparently more sensitive 
to the cytotoxic properties of the hydrophobic moieties.  
Constitutional isomerism has a significant effect on the viability pattern of the cells, with 
T-cyC6 inhibiting the growth of MCF7 while increasing HeLa and 3T3 viability, contrasting with T-
C6 that only boosted the growth of MCF7. On the other hand, the stereoisomeric nature of the 
terminal group had little effect on the preferential cell viability, as demonstrated by comparing 
the cases of the two T-Phe NPs (L and D), as well as the three different sugar functionalized NPs 
(T-Glu, T-Man and T-Gal). This observation was surprising, as a dissimilar behavior was expected 
to arise from the different levels of specific receptors at the surfaces of the cells, e.g., HepG2 cell 
contains galactose receptor while HeLa cell does not.41 It is important to note that despite the fact 
that the surface coverage with the AuNPs may be affected by the differences in the chemical 
nature of the ligand, the coverage (Figure 2.10, measured by ICP-MS) has a weak correlation with 
the observed changes in cell viability, strengthening our hypothesis that the principle factor to 
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Figure 2.10. Cell viability variations induced by different kinds of AuNP coatings. R2 values of 
linear fitting are -0.012, 0.175, 0.012 and 0.067 for HepG2, MCF7, HeLa and 3T3 groups, 
respectively. 
 
In conclusion, we developed a facile strategy to generate robust surfaces coated with 
AuNP monolayers. As shown by our preliminary studies, the surfaces are tunable in an “atom-by-
atom” fashion, allowing the exploration of a wide variety of surface chemistries. The ability to 
foster the selective growth of specific cell types makes these surfaces promising for medical 
applications such as wound healing and transplantation. Finally, the ready scalability of the 
deposition process makes these surfaces attractive for real-world manufacturing.  
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MODULATION OF STEM CELL DIFFERENTIATION BY NANOPARTICLE FUNCTIONALIZED 
SURFACES  
3.1. Introduction 
Stem cells are a promising platform for regenerative therapies due to their intrinsic self-
renewal properties and ability to differentiate into diverse cell types.1 Modulation of stem cell 
proliferation and differentiation into a specific cell type is typically achieved through the use of 
defined culture media containing specific growth factors and small molecule effectors.2 Recently, 
studies revealed that supporting matrices also play an important role in controlling stem cell 
proliferation and differentiation.3-5 Matrix stiffness,6 roughness,7, 8 nanotopography,9, 10 and 
chemical structure11, 12 all uniquely influence the interactions between stem cells and substrates, 
thereby dictating subsequent stem cell behavior. 
Tuning the matrix surface chemistry is a potent strategy to precisely control the cellular 
growth microenvironment at the molecular level.13 The chemical properties of supporting 
materials for stem cells are generally controlled through the inherent structural design of the 
material itself12 or surface post-modification.11 Surface modification provides facile access to the 
functionalization of the supporting matrix and offers more versatility than other methods.14 For 
example, polytetrafluoroethylene sequentially treated with multiple types of plasma exhibited 
enhanced osteogenesis in mesenchymal stem cells (MSCs).15 Furthermore, glass surfaces dip-
coated with different functional groups induced stem cell differentiation.16 However, due to the 
restricted range of conjugation strategies between substrata and coating layers, dip-coating is 
typically restricted to glass,17 silicon18 and gold19 surfaces. Developing more general dip-coating 
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approaches for the modulation of stem cell proliferation and differentiation would greatly 
improve the versatility of this method.  
We have recently developed a facile strategy to rapidly generate robust monolayers of 
positively charged 2-nm gold nanoparticles (AuNPs) on plastic cell culture plates via a dip-coating 
process.20 Attached through strong and stable electrostatic interactions, these AuNP-coated 
surfaces featured tunable functionality, and could be used to provide cell type-specific 
modulation of growth without uptake of AuNPs into the supported cells. This method enables the 
surface fabrication with minimal mechanic modulation through a monolayer of 2-nm gold 
nanoparticles. We hypothesized that the ability to control cellular responses by these 
nanomaterial surfaces could be extended to the modulation of stem cell differentiation. Herein, 
we report an alternative surface functionality-dependent strategy to modulate the proliferation 
and differentiation of MSCs using tunable AuNP-coated surfaces (Figure 3.1).  We show that the 
differentiation of MSCs into adipocytes and osteoblasts can be readily controlled via choice of 





Figure 3.1. Schematic representation of the strategy developed to control MSC differentiation 
using tunable AuNP-coated surfaces. 
3.2 Methods 
3.2.1 AuNP coating 
2-nm AuNPs were synthesized according to our previous report.20 AuNPs were dissolved 
in Milli-Q water at a concentration of 100 nM prior to coating. Then 500 µL of AuNP solution were 
incubated in one well of a 24-well plate at 37 °C for 3 h (125 µL for 96-well plate). Excess AuNPs 
were washed away with water three times followed by complete drying at 37 °C. 
3.2.2 AFM imaging 
For AFM characterization, the bottom of the plate coated by AuNPs was carefully 
removed and collected. AFM imaging was performed on a DI Dimension-3100 AFM. The AFM 
images and cross section profiles were processed using Gwyddion, a freeware with the agreement 
of GNU General Public License. 
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3.2.3 Cell culture 
 hTERT mesenchymal stem cells were cultured in a humidified atmosphere (5% CO2) at 
37 °C, and grown in Dulbecco’s Modified Eagle’s Medium (DMEM, low glucose) supplemented 
with 10% fetal bovine serum (FBS), 1× non-essential amino acids, 1 mM sodium pyruvate and 1% 
antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). To culture cells on the plates, 
30,000 or 7,500 cells were plated on 24- or 96-well plates for a desired time (24 hrs, 3, 7 or 14 
days), respectively.   
3.2.4 Cell differentiation 
After 24 hrs culture on plates, the media of cells were replaced with induction media that 
containing base media (R&D Systems, CCM007) and differentiation supplements (R&D Systems, 
CCM011 for adipogenesis or R&D Systems, CCM008 for osteogenesis). Differentiation media were 
replaced every 3.5 days until reaching 7- or 14-day point. 
3.2.5 AuNPs cell-uptake test 
Cells were cultured on TTMA AuNP coated plate under undifferentiated condition for one 
day, allowing them to reside on the surface. Then the media were changed to adipogenic or 
osteogenic media and replaced with fresh ones after 3 days. With the culture for another 3 days, 
cells were trypsinized and collected. For sample preparation for inductively coupled plasma mass 
spectrometry (ICP-MS), collected trypsin solutions were transferred to eppendorf tubes and 1 mL 
aqua regia was added for digestion for 15 minutes. Leftover plates were digested by 0.5 mL aqua 
regia for 15 minutes as well. Then all the samples were transferred to 15 mL centrifuge tubes 
prewashed in 5% nitric acid solution for 2 days and were diluted to 10 mL with milli-Q water. The 
ICP-MS analyses were performed on a Perkin-Elmer NexION 300X ICP mass spectrometer. 197Au 
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was measured under standard mode. Operating conditions were as follows: nebulizer flow rate: 
0.95 L/min; rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms. A series of 
standard gold solutions (concentration: 0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared to draw 
for quantification. 
3.2.6 Cell viability assay 
7,500 cells were cultured in a 96-well plate for 24 hrs with or without AuNP coating. Cells 
were then incubated with 200 μL DMEM containing 10% Alamar Blue. Cells growing in untreated 
wells were set as “Blank” group. The “Untreated” group was set by adding the same volume of 
the Alamar Blue media into the untreated wells without cells. After 3 hrs incubation, the 
fluorescence intensity (FI) of reduced Alamar Blue at 590 nm from each well was recorded with 
an excitation wavelength of 535 nm. By defining the cell viability of Blank as 100%, the viabilities 
of cells growing on AuNP coated wells were calculated using the following equation: 




Where FIBlank is the average fluorescence intensity of “Blank” group and FIuntreated is the 
average fluorescence intensity of “Untreated” group. 
3.2.7 Cell fixation 
 Before fixation, cells were washed 3 times with PBS. The cells were then fixed with 4% 
(w/v) paraformaldehyde for 10 min at room temperature. After that, paraformaldehyde solution 
was removed and cells were washed with PBS for 3 times for further tests. 
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3.2.8 Characterizations for osteogenesis 
For alkaline phosphatase activity assay, fixed cells were stained with Vector® Blue 
substrate (Vector Laboratories, SK-5300) following its protocol. To stain for calcium deposits, fixed 
cells were incubated in 0.5 % Alizarin Red S solution (pH 4.3) for 30 min at room temperature. 
After removing the staining solution, cells were washed with PBS for 3 times followed by optical 
microscope imaging. After that, cells were dried and 200 µL 10% acetic acid solution was 
employed for each well in 24 well plate to extract the dye. Calcium deposits were quantified by 
measuring the absorbance of Alizarin S at 556 nm. 
3.2.9 Characterizations for adipogenesis 
For Oil Red O staining, fixed cells were stained with 0.3% Oil Red O in 60% isopropanol 
solution for 20 min. After removal of the staining solution, cells were immediately washed with 
MilliQ water for 4 times followed by optical microscope imaging. After that, cells were dried and 
Oil Red O were extracted by isopropanol. The amount of fat droplets in cells after adipogenesis 
was quantified by measuring the absorbance of Oil Red O at 570 nm.  For western blot analysis, 
fresh cells in 24 well plates were first washed once with cold PBS, and then lyzed by 100 μL freshly 
prepared RIPA buffer supplemented with protease inhibitor cocktails (Promega, G6521). The 
lysates were then clarified by centrifugation for 10 min. at 4 °C. The protein concentration was 
determined using BCA Protein Assay Kit (Pierce, 23227). Total cell lysate protein (30 μg) was 
separated on 12% SDS PAGE gel and then transferred to a PVDF membrane (200 mA for 120 min). 
After blocking the blot with 5% non-fat milk in Tris buffered saline with Tween-20 (TBST, pH 7.4) 
for 1 hr, the membrane was incubated with rabbit anti-FABP4 (GeneTex, GTX116036; 1:500) or 
anti-β-actin (BioSS, bs-0061R; 1:1000) in 5% non-fat milk TBST solution for overnight. After 
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incubation in 5% non-fat milk in TBST with goat anti-rabbit IgG-HRP antibody (1:10000) for 1 hr, 
bands were then visualized using the ECL system. 
 
3.3. Results and Discussion 
The surfaces used for MSC culture were generated by dip-coating positively charged 
AuNPs onto the surface of negatively charged commercial cell culture plates. The coating 
materials and procedures were the same with our developed method. Briefly, the cell culture 
plate surface was incubated with 100 nM AuNP solution for 3 hrs to provide a monolayer of 
AuNPs. Surface analysis using atomic force microscopy revealed similar surface roughness before 
and after AuNP coating (Figure 3.2) compared to our previous report.20 In addition, this coating 
layer is quite robust and resists cell uptake under adipogenic or osteogenic conditions for one 
week (Figure 3.3). These results indicated that the process generated a robust monolayer of 
AuNPs on the cell culture surface.20 Since positively charged surfaces promote MSC adhesion and 
affect cell behavior,21 we reasoned that MSCs could be further modulated through the 
combination of positive charge and other surface properties. Thus, we chose five different 
positively charged AuNPs, namely TTMA, C10, Arg, DAH and Benzyl for dip-coating (Figure 3.1). 
The ligands for TTMA, C10 and Benzyl AuNPs have different quaternary amine groups, 
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Figure 3.2. AFM image and cross section profile of untreated cell culture plate, water-treated 
cell culture plate and TTMA AuNP-treated cell culture plate. The RMS roughness was obtained 

















Figure 3.3. Cell-uptake test of TTMA AuNP monolayer. The cells were cultured on the TTMA 
AuNP monolayer in a 24-well plate under adipogenic or osteogenic induction conditions for one 
week. A 24-well plate coated with TTMA AuNPs without cells cultured on the surface was used 
as a control. 
 
We performed a seven-day proliferation assay without induction to determine whether 
MSCs respond differently to the positively charged AuNP monolayers. After 1 h of incubation, 
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MSCs adhered to all surfaces (Figure 3.4), indicating biocompatibility of these surfaces. After 24 
hrs, cells grown on AuNP monolayers showed similar morphology and viability than those cultured 
on a standard plastic surface (Figure 3.5 and Figure 3.6). However, dramatic differences were 
observed after 3 days of culture. TTMA, C10, Arg and DAH AuNP monolayers increased MSC 
proliferation by more than 50%, whereas the Benzyl AuNP monolayer inhibited cell proliferation. 
These results are in agreement with our previous finding that positively charged AuNP monolayers 
generally promote cell proliferation.20 After 7 days, all except Benzyl AuNP monolayers (which 
prevented proliferation) showed similar proliferation trends (Figure 3.5). Further comparison of 
cell densities with those at 24 hrs revealed that such trend is presumably due to cell confluence 
(Figure 3.7). The results of proliferation assay and cell density analysis are consistent, indicating 
that positively charged surfaces generally enhance MSC proliferation, while the benzene ring on 
the surface of substrates strongly suppress MSC growth, possibly due to its hydrophobicity22 or 
high MSC sensitivity to aromatic functionality.21  
 
 
Figure 3.4. MSCs grown on differential functional positively charged AuNP-coated surfaces for 1 





Figure 3.5. Proliferation assay of MSCs grown on surfaces functionalized with different positively 
charged AuNPs for 1 day, 3 days and 7 days.  
 
 
Figure 3.6. MSCs grown on differential functional positively charged AuNP-coated surfaces for 





Figure 3.7. MSCs grown on differential functional positively charged AuNP-coated surfaces for 7 
days. Scale bars: 100 µm. 
 
We then performed a seven-day proliferation assay on MSCs under induced 
differentiation conditions. Prior to the differentiation, MSCs were allowed to adhere to the plates 
for 24 hrs. Next, the cells were cultured in either adipogenic or osteogenic media for 7 days. TTMA, 
Arg and DAH AuNP monolayers showed no toxicity to MSCs under differentiation conditions. 
However, under both induction conditions, MSCs grown on Benzyl AuNP monolayer did not 
survive (Figure 3.8). Thus, Benzyl AuNP monolayers not only affect cell proliferation negatively, 
but also induce cell death during differentiation. C10 AuNP monolayers induced almost complete 
cell death after 7 days in the presence of adipogenic but not osteogenic induction media. The 
structure of C10 AuNP resembles that of TTMA AuNP but with higher hydrophobicity. In fact, both 
these monolayers were similarly able of supporting MSC growth under non-differentiation or 
osteogenic condition. Hence, increased hydrophobicity of the supporting surface does not favor 
adipogenesis in MSCs. This property may have implications for the selective inhibition of 
adipocyte generation in the treatment of obesity and other diseases. 
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Figure 3.8. Proliferation assay of MSC on various positively charged AuNP-coated surfaces after 
7 days induction in differentiation media: a) Adipogenic inducing media; b) Osteogenic inducing 
media.  
 
We next investigated the modulatory capability of AuNP monolayers on osteogenic 
differentiation of MSCs. Osteogenesis plays an important role in bone maintenance and repair.23 
Impaired osteogenesis results in osteoporosis while excessive osteogenesis may cause 
hyperostosis.24 Even though the modulation of MSC osteogenic differentiation has been achieved 
by tuning the stiffness of the supporting material,25 chemical cues for osteogenesis control 
provide additional benefits, including precision at the atomic level, high-throughput screening and 
rapid modification. Herein, TTMA, C10, Arg and DAH AuNP monolayers were used to support cell 
growth and differentiation as functionalized surfaces. Neutral (OH) and negatively charged 
(COOH) AuNPs were utilized as controls, as well as the surface without AuNP coating. After 
osteogenic induction for 14 days, the cells were analyzed for alkaline phosphatase activity. 
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Alkaline phosphatase is a marker for MSC derived osteoblasts26 (MSC progenitors do not express 
alkaline phosphatase27). After 14 days of osteogenic induction of MSC growth on the defined 
surfaces, a change in alkaline phosphatase activity was observed (Figure 3.9). Specifically, MSCs 
cultured on the DAH AuNP monolayer showed 40% higher alkaline phosphatase activity, when 
compared to cells grown on the surface without AuNP coating. On the other hand, in MSCs 
cultured on the TTMA AuNP monolayer, the alkaline phosphatase activity decreased 70% (Figure 
3.10). Cells differentiated on other surfaces barely showed any difference with regard to alkaline 
phosphatase activity. These results indicate that chemically defined surfaces modulate osteogenic 
differentiation of MSCs. 
 
 
Figure 3.9. Vector® Blue staining for alkaline phosphatase activity after osteogenic induction for 






Figure 3.10. Osteogenesis of MSCs is modulated by AuNP-coated surfaces. a) Normalized 
differentiation ratio of induced cells grown on AuNP-coated surfaces after 14 days, 
marked by alkaline phosphatase expression level. b) Normalized calcium mineralization 
of osteoblasts, determined by Alizarin Red S staining.  
 
To further confirm the osteogenic differentiation of MSCs, it is necessary to quantify the 
level of functional osteoblasts. Since mineralization of calcium is a key indicator of functional 
osteoblast, we then analyzed calcium deposition to evaluate MSC osteogenic differentiation. All 
surfaces were incubated with Alizarin Red S so that the calcium deposits were visible as red 
aggregates28 (Figure 3.11). Quantitative analysis revealed that MSCs cultured on Arg and DAH 
monolayers produced more calcium deposits than the controls, whereas the TTMA AuNP 
monolayer inhibited calcium deposition. This result is in agreement with the alkaline phosphatase 
assays. The amine functional group has been reported to generally elevate the osteogenic 
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differentiation ratio.16, 29 Our results further demonstrate that primary, but not quaternary, 
ammonium groups promotes MSC osteogenesis. Also, the increased calcium deposits with the 
Arg surface suggest that phenotypic control by the surface extends beyond differentiation. 
 
 
Figure 3.11. Cells stained with Alizarin S (red) and Vector® Blue (blue) after osteogenic induction 
for 14 days. Scale bars: 100 µm. 
 
We then tested whether these AuNP monolayers were capable of modulating the 
adipogenic differentiation of MSCs. C10 and Benzyl AuNP monolayers were excluded from these 
experiments because of their toxicity in MSCs undergoing adipogenesis (Figure 3.8). Since the 
adipose-specific protein FABP4 is a known marker for adipogenesis,30 the expression levels of 
FABP4 in MSCs were determined after 7 and 14 days of adipogenic differentiation (Figure 3.12a). 
At the seven-day point of differentiation, the expression level of FABP4 was elevated in MSCs 
grown on the TTMA AuNP monolayer. After 14 days of incubation, this enhancement was more 
pronounced (Figure 3.12b). Slight elevation of FABP4 expression was also observed in MSCs 
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cultured on the Arg AuNP monolayer, whereas MSCs cultured on the remaining surfaces 
expressed similar levels of FABP4 than controls. 
 
 
Figure 3.12. Adipogenesis of MSCs is modulated by AuNP-coated surfaces.  a) FABP4 
expression of induced cells grown on AuNP-coated surfaces after 7 days. b) FABP4 
expression of induced cells grown on AuNP-coated surfaces after 14 days. c) Normalized 
differentiation ratio determined by Oil Red O staining.  
 
Other than analyzing the expression marker, it is important to determine the function of 
adipocytes. Once adipocytes formed, fat droplets started to accumulate. As lipid droplets can be 
marked with Oil Red O;28 this dye was used to detect and quantify MSC adipogenic differentiation. 
Microscope imaging revealed that numerous cells contained fat droplets after a 14-day induction 
(Figure 3.13). MSCs cultured on the TTMA AuNP monolayer exhibited the strongest Oil Red O 
staining. Quantitative analysis of Oil Red O indicated that adipogenic differentiation of MSCs 
grown on TTMA AuNP monolayers increased 83% when compared to surfaces without AuNP 
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(Figure 3.12c). In addition, the other AuNP monolayers did not show significant difference in Oil 
Red O staining when compared to the controls, which is consistent with the FABP4 expression 
results (see above). Taken together, our findings indicate that TTMA AuNP monolayers specifically 




Figure 3.13. Oil Red O staining of cells after adipogenic induction for 14 days. Scale bars: 50 µm. 
3.4 Conclusion 
In summary, we have developed a facile and scalable strategy to modulate mesenchymal 
stem cell proliferation and differentiation. As shown in this study, the chemical properties of the 
surfaces are precisely tuned at the molecular level through deposition of engineered 
nanoparticles, allowing for further exploration of the modulatory capability of highly tunable 
surface chemistries in stem cell growth. Mechanistic studies on how stem cells response to subtle 
changes of their niches will also be able to be performed in vitro on these monolayers, including 
nanoparticle size, surface functionalization of nanoparticles, and functionalization density of 
nanoparticle ligands. The ability to promote modulated growth and differentiation offers great 
potential for the use of these surfaces on a variety of stem cells, as well as other cell types, in 
 
54 
medical applications such as wound healing and transplantation. Finally, because of their readily 
scalable deposition process, these surfaces will be easily adaptable for large-scale manufacturing. 
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DIRECT DELIVERY OF FUNCTIONAL PROTEINS AND ENZYMES TO THE CYTOSOL USING 
NANOPARTICLE-STABILIZED NANOCAPSULES 
4.1 Introduction 
Protein-based therapeutics are promising tools for numerous biomedical applications.1 
Intracellular delivery of functional proteins to replace missing, dysfunctional or poorly-expressed 
proteins, or antagonize key intracellular pathways is the fastest growing and a promising arm in 
modern drug development. Protein-based biologics have provided new therapeutic avenues for 
cancer,2, 3 and have also been used to treat a range of disease states including inflammation,4 
lysosomal storage diseases,5 and transient cerebrovascular disorders.6 In addition to therapeutics, 
direct cytosolic delivery of functional proteins provides a potential tool for important biological 
applications including imaging,7 signaling studies,8, 9 cellular10, 11 and stem cell engineering.12  
A major complication in the use of protein-based drugs is the difficulty of delivering the 
unmodified, functional protein in an active conformation to the necessary site of action. 
Mechanical delivery methods, such as microinjection and electroporation have been used in 
research for decades.13 These methods, however, are low-throughput, disruptive, and require 
specialized equipments to mechanically/physically puncture membranes, limiting their utility for 
in vivo applications. Another promising approach for delivering proteins utilizes covalent 
carriers14, 15 that require irreversible modifications of the protein cargo. 16, 17  However, these 
covalent modifications of protein may impact protein function by interfering with protein 
folding.18 Furthermore, covalent modification of proteins for delivery is not a general approach; 
in cases where this strategy works customized optimization protocols tailored to each specific 
protein are required.14  
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A major challenge in all the non-mechanical protein delivery strategies described above 
is access of the protein to the cytosol. Most delivery strategies rely on endocytic mechanisms of 
cellular uptake.19 As a result, the delivered proteins are susceptible to degradation in the 
endosome/lysosome and are also unable to access key subcellular structures and machineries 
required for most applications.15 Currently, prolonged incubation times, elevated concentrations 
of delivery agents, and lysosomotropic reagents (such as chloroquine) are required to increase 
the efficiency of endosomal escape of delivered proteins.20, 21  
Supramolecular carrier-based delivery methods are modular, easy to formulate, and 
operate through reversible associations with target proteins.22 In non-covalent strategies, 
proteins and delivery vectors self-assemble, allowing the transport of unmodified proteins into 
the cell and overcome the limitations of using covalently protein modification strategies.14, 15  
We have recently developed a nanoparticle-stabilized capsule (NPSC) system for the 
delivery of hydrophobic drugs.23 These NPSCs rapidly released small molecule payloads from their 
oil interior through a membrane fusion-like24, 25 hydrophobic interaction with the cell membrane. 
We hypothesized that this vehicle could also be used for cytosolic protein delivery by 
incorporating functional proteins into the NPSC shell. In this report, we demonstrate rapid and 
efficient delivery of therapeutic and imaging proteins into the cytosol of HeLa cells using NPSCs. 
Caspase-3 (CASP3) was chosen to demonstrate therapeutic delivery of an active, biomedically 
important enzyme. Delivery of CASP3 is a particularly stringent test of the efficacy of this 
approach, as caspases are delicate enzymes that would be susceptible to inactivation during the 
delivery process. CASP3 was efficiently delivered into cells, resulting in effective induction of 
apoptosis. Green fluorescent protein (GFP) was used to determine the intracellular distribution of 
delivered proteins. The delivered GFP was distributed throughout the cell with identical cellular 
distribution to that of endogenously expressed red fluorescent protein (RFP). Further proof of 
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cytosolic access was demonstrated through efficient intracellular targeting of a GFP fusion protein 
to the peroxisome.26  
4.2 Methods 
4.2.1 Protein-NPSC complex preparation 
The HKRK ligand protected AuNPs (HKRK AuNPs) were synthesized following reported method. To 
make the protein-NPSC complex, 2.5 μM HKRK AuNPs were incubated with 1 μM GFP in 30 μL 
phosphate buffer (5 mM, pH = 7.4) for 10 min. Then, 1 μL of the mixture of linoleic acid and 
decanoic acid (molar ratio = 1:1) was mixed with 500 μL of phosphate buffer (5 mM, pH = 7.4) 
containing 1 μM HKRK AuNPs and agitated by an amalgamator at 5000 rpm for 100 s to form 
emulsions. Finally, the mixture of the protein and HKRK AuNPs was diluted to 45 μL with 
phosphate buffer (5 mM, pH = 7.4) followed by the addition of 5 μL of the emulsion. The protein-
NPSC complexes were ready to use after 10 min incubation at room temperature. The 
concentration of NPSC was 0.29 nM, calculated according to reported method. The final 
concentrations of HKRK AuNPs and GFP were 1.5 μM and 600 nM, respectively. 
4.2.2 GFP expression and purification 
Starter cultures from a glycerol stock of BL21(DE3) housing the gene for Enhanced GFP (EGFP) 
with an N-terminal 6-His tag in the pET21b expression vector (Novagen) with or without the 
peroxisomal-targeting sequence 1 (PTS1) were grown overnight in 50 mL of 2 × YT media with 50 
µL of 1000× ampicillin (16 g tryptone, 10 g yeast extract, 5 g NaCl in 1 L water). The cultures were 
shaken overnight at 250 rpm at 37 °C. The following day, 10 mL of the starter cultures were added 
to a Fernbach flask containing 1 L of 2 × YT and 1 mL 1000× ampicillin and shaken until OD600 = 0.7 
was reached. The protein expression was then induced by adding IPTG (1 mM, final concentration) 
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and shaken at 28 °C. After 3 h, the cells were harvested by centrifugation (5000 rpm for 15 min at 
4 °C). The pellet was then resuspended in lysis buffer (2 mM imidazole, 50 mM NaH2PO4, 0.3 M 
NaCl) and the cells were lysed using a microfluidizer. Cell lysate was centrifuged at 15,000 rpm for 
45 min at 4 °C. The GFP was purified from the supernatant using an imidazole gradient on a HisPur 
(Thermo Scientific) Cobalt column. The imidazole used for elution was removed from the GFP 
sample by dialysis in 5 mM sodium phosphate buffer (pH = 7.4). 
4.2.3 Caspase-3 expression and purification 
The caspase-3 full-length human gene in the pET23b vector (Addgene) was used for 
expression of caspase-3. The procedure is similar as GFP expression and purification. The 
supernatant was loaded onto a 5 mL HiTrap Ni-affinity column (GE Healthcare). The column was 
washed with a buffer of 50 mM Tris pH 8.5, 300 mM NaCl, 5% glycerol and 50 mM imidazole. The 
caspase-3 protein was eluted with a buffer containing 50 mM Tris pH 8.5, 300 mM NaCl, 5% 
glycerol and 250 mM imidazole. The eluted fraction was diluted 9-fold into a buffer containing 20 
mM Tris pH 8.0 and 2 mM DTT to reduce the salt concentration. This protein sample was loaded 
onto a 5 mL Macro-Prep High Q column (Bio-Rad Laboratories, Inc.). The column was developed 
with a linear NaCl gradient and caspase-3 eluted in a buffer of 20 mM Tris pH 8.0, 120 mM NaCl 
and 2 mM DTT. The eluted protein was stored at -80 °C in the elution buffer conditions. Caspase-
3, analyzed by SDS-PAGE to be ~98% pure was further analyzed by ESI-MS to confirm mass. 
4.2.4 Cell culture 
HeLa cells were cultured in a humidified atmosphere (5% CO2) at 37 °C, and grown  in 
Dulbecco’s modified  eagle’s  medium  (DMEM, low  glucose) supplemented with  10%  fetal  
bovine  serum  (FBS) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). 
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4.2.5 Cell transfection and selection 
PCDNA3.1(-)-mcherry plasmid was cloned from pCHERRY3 plasmid, purchased from 
Addgene (ID: 24659). RFP-PTS plasmid was purchased from Origene. HeLa cells were transfected 
by lipofectamine 2000 according to manufacturer's protocols (Invitrogen). The transfected cells 
were then selected by geneticin (Invitrogen) at the concentration of 400 µg/mL in DMEM with 
10% FBS until the stably transfected clones were obtained.  
4.2.6 Fluorescence titration 
In the fluorescent titration experiment between nanoparticles and GFP, the change of 
fluorescence intensity at 515 nm was measured with an excitation wavelength of 485 nm at 
various concentrations of NPs from 0 to 200 nM on a Molecular Devices SpectraMax M3 
microplate reader (at 25 °C). Decay of fluorescence intensity arising from 100 nM GFP was 
observed with increasing NP concentration. Nonlinear least-squares curve fitting analysis was 
carried out to estimate the binding constant (Ks).27 
4.2.7 GFP delivery 
60,000 or 240,000 HeLa cells or transfected HeLa cells were cultured in a 24-well plate or 
confocal dish, respectively, for 24 h prior to delivery. The cells were washed by cold phosphate 
buffer saline (PBS) 3 times right before delivery. After the preparation of cells, GFP-NPSC complex 
solution (50 μL or 150 μL of the GFP-NPSC complex diluted by 450 μL or 1.35 mL of the DMEM 
without FBS, respectively) was incubated with the cells for 1 h in a 24-well plate or confocal dish, 
and followed by incubation with fresh DMEM with 10% FBS for 1h unless otherwise mentioned. 
To study the colocalization with Hoescht 33342 or Lysotracker, the reagent was introduced 20 
min before the observation. 
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4.2.8 CASP3 delivery 
The procedure of CASP3 delivery was similar to that of GFP delivery, except that 30,000 
HeLa cells were incubated in a 24-well plate for 24 h prior to delivery. After the protein delivery, 
the cells were stained by Yopro-1 and 7-AAD for 30 min, followed by the observation under 
fluorescence microscope. The apoptotic ratio of each sample was calculated as the ratio of 
fluorescently stained cells over 100 cells.  
4.2.9 Cell viability assay (Alamar Blue) 
7,500 HeLa cells were cultured in a 96-well plate for 24 h prior to the experiment. The cells were 
washed by cold phosphate buffer saline (PBS) 3 times before the delivery, then different amounts 
of the GFP-NPSC complex (prepared as mentioned above) were diluted by DMEM and incubated 
with the cells for 1 h followed by the incubation with DMEM containing 10% FBS and 1% 
antibiotics for 23 h. After washing with PBS 3 times, the cells were then incubated with 200 μL 
DMEM containing 10% Alamar Blue for 3 h. Cell viability was calculated by measuring the 
fluorescence intensity of Alamar Blue at 590 nm, with an excitation of 535 nm.  
4.2.10 In vitro caspase-3 activity assay 
For kinetic measurements of caspase activity, 20 nM  protein with and without 40 nM 
HKRK AuNPs were assayed over the course of 5 minutes in a caspase-3 activity-assay buffer 
containing 20 mM Tris (pH 7.5) and 5 mM TCEP. 150 µM substrate (DEVD-AMC [N-acetyl-Asp-Glu-
Val-Asp-AMC], Enzo Lifesciences; Ex. 365 nm / Em. 495 nm) was added to initiate the reaction. 
Assays were performed in triplicate at 25°C in 100 μL volumes in 96-well microplate format using 
a Molecular Devices Spectramax spectrophotometer.  
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4.2.11 Live cell imaging 
240 K HeLa cells were cultured in the confocal dish 24 hr prior to the experiment. Before 
live cell imaging, cells were washed by PBS for three times followed by the incubation with GFP-
NPSC in cell culture media. The confocal dish was then placed in the live cell imaging chamber 
with 5% CO2 and at 37 °C on the confocal microscope. A series of images were taken at certain 
time intervals. 
4.3 Results and Discussions 
4.3.1 Nanoparticle-stabilized capsule fabrication 
 The protein-NPSC (CASP3-NPSC and GFP-NPSC) complexes were generated using a 
convergent process (Figure 4.1a), where the HKRK AuNPs (see Figure 4.1a for the structure) 
provided a dual mode supramolecular stabilization of the capsule wall. Briefly, proteins and AuNPs 
were mixed and incubated at room temperature for 10 minutes. Template emulsions were 
formed by homogenizing AuNPs in phosphate buffer (5 mM, pH 7.4) and oil. Protein-NPSCs were 
formed by combining template emulsions and the protein-AuNP mixture. Combined hydrogen 
bonding and electrostatic interactions between the guanidinium moieties of the particles and the 
carboxylates of the oil28, 29 pin the nanoparticles to the capsule surface. Lateral stabilization is 
provided through interactions of the cationic nanoparticles with the anionic proteins (GFP pI= 5.9, 
CASP3 pI= 6.1) to be transported (Figure 4.1a).30 The capsule size is well-controlled and in a regime 
well suited for intracellular delivery31 with GFP-NPSCs and CASP3-NPSCs possessing average 
diameters as determined by dynamic light scattering of 130 ± 40 nm and 140 ± 20 nm, respectively 




Figure 4.1. Design and preparation of nanoparticle-stabilized capsules (NPSCs). (a) Schematic 
showing the preparation of the protein-NPSC complex containing caspase-3 or GFP and 
proposed delivery mechanism. The oil was a 1:1 mixture of linoleic acid (LA) and decanoic acid 
(DA). (b) TEM image of the dried GFP-NPSC. (c) Dynamic light scattering (DLS) histogram of GFP-
NPSCs indicating an average diameter of 130 ± 40 nm.  
 
 




A fluorescence titration was performed to measure the binding constant (Ks) between 
HKRK AuNPs and GFP, which was found to be 9 × 107 M-1, indicating high affinity of HKRK AuNPs 
to the protein (Figure 4.3a). Screening of the electrostatic interactions through the use of 500 mM 
NaCl into the mixture of AuNPs with GFP at 1:1 molar ratio resulted in complete recovery of the 
GFP fluorescence (Figure 4.3b), indicating reversible electrostatic interactions between the HKRK 
AuNP and the protein. GFP is almost completely quenched upon complexation by AuNPs. NPSC 
formation, however, results in a partial restoration in fluorescence. This result indicates a change 
in the structure of GFP-AuNP complex when at the interface of the NPSCs. To further probe the 
nature of the interactions, the NPSCs were incubated in 0.5% Tween-20 and 500 mM NaCl 
solutions.  The high salt solution resulted in no change in fluorescence, while Tween-20 resulted 
in increased in fluorescence. (79%; Figure 4.4a).  These results suggest that other interactions are 
involved in NPSC assembly beyond simple electrostatics. For CASP3, enzyme activity was assessed 
after interaction with HKRK AuNPs. Activity assays in vitro showed that the interaction between 
CASP3 and HKRK AuNPs did not inhibit the enzymatic activity. In fact, HKRK AuNPs enhanced the 
CASP3 activity by 2.3 times, a phenomenon observed previously in other nanoparticle-protein 
systems32 (Figure 4.4b). While efforts were made to assess activity of CASP3 in the NPSCS, the 
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Figure 4.3. Determination of the interaction between GFP and HKRK AuNPs. (a) Fluorescence 
titration of HKRK AuNPs in the presence of 100 nM GFP in 5 mM phosphate buffer (pH = 7.4). 
The binding constant (Ks) and association stoichiometry (n) were calculated through the fitting 
using the model of single set of identical binding sites.33 (b) Fluorescence recovery of 100 nM 
GFP quenched by 100 nM HKRK AuNPs in the presence of 500 mM NaCl or phosphate buffer 
(control). 














































































20 nM CASP3 with 40 nM HKRK AuNPs
Activity: 8.29 ± 0.13 RFU/s
20 nM CAS3
Activity: 3.59 ± 0.06 RFU/s
 
Figure 4.4. (a) Fluorescence recovery of GFP quenched by NPSC.  The concentrations of both 
GFP and AuNP are 400 nM in 100 µL mixture. The concentration of NaCl is 500 mM and that of 
Tween-20 is 0.5% by volume. (b) In vitro activity assay of CASP3 in the presence or absence of 
HKRK AuNPs. 
 
4.3.2 Therapeutic protein delivery with NPSCs 
 Effective use of therapeutic proteins for intracellular applications requires rapid delivery 
of the protein in the active form to the cytosol.34, 35  CASP3 is a highly promising therapeutic 
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protein candidate36 owing to its critical role in apoptosis.37 Most tumor cells do not undergo 
appropriate apoptosis, which leads to unhindered cell growth.38 In many tumor cells CASP3 
function is blocked due to over expression of inhibitor of apoptosis (IAP) proteins that directly 
inhibit caspase function preventing apoptosis. Intracellular delivery of sufficient levels of active 
CASP3 into the cytosol of such tumor cells circumvents this blockage, allowing tumor cells to enter 
apoptosis. Delivery of active caspases is extremely challenging, however, due to the negative 
charge and heterotertrameric state of the protein, the susceptibility of the active site to oxidation 
and alkylation, and the fragile nature of the active site that is composed of four highly mobile 
loops. 
Demonstration of effective delivery of active CASP3 was established through incubation 
of HeLa cells with CASP3-NPSCs. After 1 h incubation, 72.0 ± 5.5% of HeLa cells underwent 
apoptosis, confirmed by double staining with Yopro-1 (a dye to detect apoptotic cell nuclei)39 and 
7-AAD (a dye used to detect membrane disruption)40 (Figure 4.5a). The NPSC itself (Figure 4.5b), 
CASP3 only (Figure 4.5c), or CASP3 with AuNPs induced minimal levels of cell apoptosis, 







Figure 4.5. Delivery of caspase-3 into HeLa cells. Cells were incubated for 1 h with (a) CASP3-
NPSC, (b) NPSC without CASP3, and (c) only CASP3 without NPSC. Subsequently, cells were 
stained using Yopro-1 (green fluorescence) and 7-AAD (red fluorescence) for 30 min, and the 
overlapped images are presented as apoptotic. (d) Apoptosis ratios of the cells after CASP3 
delivery. Scale bars: 100 µm; the error bars represent the standard deviations of three parallel 
measurements. 
4.3.3 GFP delivery using NPSCs 
The effectiveness of the delivered caspase suggested access of the delivered protein to 
the cytosol. The capability of cytosolic delivery of NPSCs was verified using GFP. Imaging 
experiments were performed using live cells to provide an accurate determination of protein 
distribution inside the cell.41 After 1 h incubation of GFP-NPSCs with HeLa cells, followed by 1 h 
incubation in fresh media, GFP was observed evenly distributed throughout the cytosol and 
nucleus (Figure 4.6a). In comparison, no delivery was observed by mixing empty NPSCs and GFP, 
indicating that the NPSCs serve as a carrier for the delivery cargo and not solely as a "hole 
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puncher" for membrane penetration (Figure 4.7). To further demonstrate the cytosolic 
distribution of GFP, NPSCs were used to deliver GFP into mCherry expressing HeLa cells.42 Confocal 
images (Figure 4.6b and Figure 2.8) show GFP delivered via NPSCs to be evenly distributed 
throughout the cytosol and nucleus (with the exception of nucleoli) of HeLa cells, with no 
perceptible difference in distribution with respect to mCherry. Co-administration of Hoechst 
33342 (a family of blue fluorescent dyes used to stain nuclei) confirmed that the delivered GFP 
had gained access to the nucleus, but not to the interiors of nucleoli (Figure 4.9), consistent with 
the distribution of cellularly expressed mCherry. Dispersal of GFP in the nucleus indicated that 
GFP was successfully delivered not just to the cytosol, but also to the nucleus by free diffusion 
through nuclear pores.43 Taken together, these results demonstrate that the GFP was successfully 
delivered into the cytosol in a freely diffusing fashion.  
Figure 4.6. Delivery of GFP into HeLa cells. (a) Confocal image showing GFP delivery into HeLa 
cells by NPSCs. (b) Confocal images showing the colocalization of delivered GFP with expressed 
mCherry in HeLa cell. (c) Flow cytometry results of HeLa cells treated with GFP-NPSCs (red), or 





Figure 4.7. Co-incubation of empty NPSC and GFP with HeLa cells for 1 hr. The bar represent 20 
µm. 
                       GFP                     mCherry (Expressed)                 Merged 
 
Figure 4.8.  HeLa cells stably express mCherry (control group for Figure 2d in context). The scale 
bar represents 20 µm. 
 
Figure 4.9. (a) Colocalization of GFP and Hoechst 33342 in a HeLa cell. (b) Magnified from boxes 




Flow cytometry was used to quantify the efficiency of GFP delivery into cells using NPSCs. 
The results showed that GFP was delivered to 77 ± 5% of cells in the GFP-NPSCs group (Figure 
4.6c), consistent with the apoptosis induction observed with the CASP3-NPSCs.  As expected, no 
delivery was observed for either the cells treated with GFP alone or untreated. Only low levels of 
delivery (20.6 ± 3.8%) were observed for GFP-HKRK AuNP complexes that were not in capsule 
form (Figure 4.10), with most of the delivered GFP remaining entrapped in late 
endosomes/lysosomes (Figure 4.11). The difference in GFP delivery efficiency and subcellular 
localization between the particle-only group and the NPSC group supports the hypothesis that the 
improved efficiency of the delivery process in the NPSC group resulted from a membrane fusion-
delivery process, in agreement with previous studies.44, 45  The NPSCs showed little cytotoxicity at 
the concentration (29 pM) used for the delivery studies (Figure 4.12). 
 
Figure 4.10. Flow cytometry results of HeLa cells cultured with GFP-HKRK AuNPs for 2 h, using 




       GFP               Late endosome/lysosome      Bright Field                        Merged 
 
Figure 4.11. Confocal image of the colocalization of GFP with late endosomes and lysosomes 
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Figure 4.12. Viability of HeLa cells at different concentrations of GFP-NPSC complexes measured 
by Alamar Blue assay. 
 
Live cell video imaging was then performed to track the intracellular release of protein 
payloads by NPSCs (Figure 4.13).  As shown in Figure 4.13, GFP-NPSCs remain intact for the first 
few minutes after attaching to the cell, confirmed by the colocalization of GFP and the AuNPs. 
Then GFP was rapidly released into cytosol within.  GFP was rapidly delivered, however the GFP-
NPSC was not taken up as an intact entity by the cell. Taken together, these results strongly 
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support the membrane fusion mechanism of delivery while demonstrating that uptake does not 
occur through an endocytotic mechanism 
 
Figure 4.13. Live cell imaging of rapid GFP release into the cytosol of HeLa cell by NPSCs. “0 min” 
label represents the starting point of release. The arrow indicates a GFP-NPSC at the cell 
membrane prior to delivery of payload. Scale bar: 20 µm.  
4.3.4 Intracellular targeting of delivered proteins 
To further demonstrate the versatility of NPSC protein delivery for intracellular delivery 
and imaging, we fused a peroxisomal-targeting sequence 1 (PTS1) to GFP (Figure 2.14).46 HeLa 
cells with stable expression of RFP bearing a C-terminal peroxisomal-targeting sequence were 
used to provide a fluorescence label for the peroxisomes. After 1 h incubation with GFP-PTS1-
NPSC complexes, followed by 1 h incubation with fresh media, the confocal images clearly 
confirmed complete colocalization of the GFP-PTS1 fusion protein with the RFP-labeled 
peroxisomes (Figure 4.15a and Figure 4.16). In contrast, GFP without the PTS1 motif was evenly 
distributed throughout the cell as previously described (Figure 4.15b). These results clearly 
demonstrate that the protein delivered by the NPSCs gained complete access to the cytosol, and 
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that proteins delivered by NPSCs are capable of targeting subcellular organelles with essentially 
identical localization behavior to cellularly expressed proteins. 
 
 
Figure 4.14. GFP fused with PTS1 motif.                                                                                            
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Figure 4.15. Peroxisome targeting in HeLa cells transfected with RFP-PTS1 plasmid. (a) 
Colocalization of GFP-PTS1 fusion protein with the peroxisomal indicator (RFP-PTS1) expressed 
by the cell. (b) No colocalization of GFP was observed without PTS1 motif. Scale bars: 20 µm. 
 
 
Figure 4.16. (a) Delivery of GFP-PTS1 into HeLa cells by NPSCs.  (b) Untreated cells under the 






We have demonstrated a rapid and efficient protein delivery strategy using nanoparticle 
based supramolecular nanocapsules. This approach provides a generalized strategy for direct 
delivery of functional proteins in their native forms.  The supramolecular structure of the NPSCs 
makes the system stable for delivery of proteins yet reversible for payload release.  In contrast 
with particle based protein delivery systems, this method is capable of overcoming the major 
challenge of endosomal sequestration and thus holds great promise for effective protein therapy 
and imaging applications. We demonstrated the efficiency of the system by delivering a functional 
therapeutic protein, CASP3 into target cells to induce apoptosis. Delivery of fluorescent proteins 
demonstrated cytosolic distribution identical to that of a cellularly expressed counterpart, with 
delivery versatility further demonstrated by subcellular targeting of proteins. Taken together, the 
ability to incorporate active proteins on the capsule shell and efficiently deliver into the cytosol 
opens up new opportunities for protein replacement therapy, in vivo disease prognosis through 
imaging, cellular organelle labeling, and cellular engineering.  
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QUANTITATIVE TRACKING OF PROTEIN TRAFFICKING TO THE NUCLEUS ENABLED BY 
CYTOSOLIC PROTEIN DELIVERY  
 5.1 Introduction 
Intracellular protein trafficking is central to all protein functions.1 Aberrant localization of 
proteins is involved in the pathogenesis of diseases such as Alzheimer’s, cancer and metabolic 
disorders.2 Monitoring protein trafficking provides an effective way to investigate the spatial and 
temporal regulation of protein systems behind basic cellular functions.3  
A key challenge in studying protein trafficking is to place the protein in the appropriate 
location of a cell. Conventionally, intracellular protein trafficking is monitored by cell 
permeabilization based methods.4 In spite of being routinely used, cell permeabilization methods 
have been extensively criticized.5 Permeabilized cells require exogenous supply of cytosol and ATP 
for subcellular transport of proteins. In particular, these methods deviate from in vivo conditions, 
and their unpredictable effects in extracting and relocating intracellular proteins in different cell 
types lead to artifacts.5 Fluorescence recovery after photobleaching (FRAP) of expressed proteins 
is another widely used approach that provides insight on the diffusional properties of the protein.6 
However, this method also has its intrinsic limitations. Quantitative analysis of the localized 
protein is not feasible by this method because of pre-existing photobleached proteins. More 
importantly, photobleaching causes oxidative stress in the cell that can result in significant 
deviation from normal cellular homeostasis.7  
Direct protein delivery provides an alternative path to overcome current challenges in the 
study of protein trafficking. Physical and mechanical approaches, such as microinjection and 
electroporation, have been used for decades.3 However, these methods are quite disruptive to 
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cells.8 Sudden and dramatic changes in intracellular homeostasis, including membrane potential 
and intracellular ionic concentrations, limit the use of these methods.8 Endocytic pathways of 
cellular entry are slow and result in considerable protein degradation and sequestration,9 
providing a challenge for standard chemical and biological delivery strategies.  
 
We have recently developed a protein delivery method using nanoparticle-stabilized 
capsules (NPSCs) that evades the endocytic pathway.10 NPSCs contain a fatty acid core and a shell 
of HKRK AuNPs and payload proteins. In this process NPSCs rapidly deliver proteins directly to the 
cytosol via transient membrane fusion.10, 11 This method allows us to deliver the targeted protein 
into the cytosol, and monitor nuclear protein trafficking in a non-disruptive fashion without 
complications arising from current strategies. (Figure 5.1a).  
5.2 Results and Disscussions 
We chose five nuclear localization signal (NLS) sequences (Figure 5.1b, Figure 5.2 and 
Tables 5.1 and 5.2), namely NLSSV40, NLSc-Myc, NLSNLP, NLSTUS and NLSEGL-13 for monitoring nuclear 
protein trafficking and comparing nuclear targeting efficiencies of the above known NLSs. These 
NLS sequences are of different size, charge and origin. NLSEGL-13, a 19-amino acid fragment derived 
from EGL-13 transcription factor,12 was attached to the N-terminus of enhanced green fluorescent 
protein (eGFP), while NLSSV40, NLSc-Myc, NLSNLP and NLSTUS were fused to the C-terminus. NLSSV40 is 
the first NLS identified from the simian virus 40 (SV40) large T antigen whereas NLSc-Myc, NLSNLP 
and NLSTUS are derived from c-Myc,13 Nucleoplasmin14 and Tus protein15 respectively. For these 
studies, eGFP rather than any functional protein was chosen as a reporter protein since it is a well-
accepted fluorescent reporter to study the distribution and dynamics of the nuclear protein 
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trafficking16 that is small enough (27 kDa) to enter the nucleus.17 Furthermore, eGFP is known not 











Figure 5.1. Delivery of eGFP fused with nuclear localization signals (NLS) to cells using NPSCs. (a) 
Schematic representing the cytosolic delivery and nuclear accumulation of proteins with NLSs. 
(b) Structure of eGFP fused with NLSs. (c) LSCM images showing different cellular distribution 
patterns of eGFP fused with NLSs. Bars: 20 µm. (d) Statistical analysis revealing nuclear 










Figure 5.2.  SDS-PAGE analysis of five NLS-eGFPs. 
 
Table 5.1. Primers for PCR cloning 








































































NPSCs containing the NLS-tagged eGFP-NPSC (NLS-eGFP-NPSC) were readily formed 
following previously reported methods10 (Figure 5.3 and Figure 5.3). Effective delivery of NLS-
eGFPs was established using laser scanning confocal microscopy (LSCM). After 1 h incubation of 
NLS-eGFP-NPSCs with HeLa cells, followed by 1 h incubation in fresh media, NLS-eGFP was 
distributed throughout the cell, with obvious accumulation in the nucleus Figure 5.1c and Figure 
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5.5). Quantitative comparison of the nuclear accumulation of the five NLS-eGFPs from LSCM 
results showed different nuclear import efficiencies (Figure 5.1d and Figure 5.6). Among the 
studied proteins, NLSc-Myc-eGFP exhibited an increase in nuclear intensity by 160% compared to 
that in the cytosol while  NLSSV40-eGFP, one of the most routinely used NLS tags, exhibited an 
increase in intensity of only ca. 45%, with a substantial amount of protein remaining in the cytosol. 
This result is in agreement with the previous observation of nuclear accumulation of intracellularly 
expressed NLSSV40-eGFP,15 but differs strongly from cell permeabilization methods that showed 
that NLSSV40-eGFP completely accumulated in nuclei.18 This difference in outcomes presumably 
arises from alterations in the distribution of soluble intracellular proteins upon permeabilization.19 
The other three NLS-eGFPs showed significant nuclear accumulation ability. NLSNLP-eGFP showed 
85% higher nuclear intensity, while that of NLSEGL-13-eGFP showed 70%. NLSTUS-eGFP displayed 
only moderate nuclear targeting efficiency, with an increase of 30%. The varied nuclear intensities 
of NLS-eGFPs were due to the differences in the nuclear targeting efficiencies of the NLSs.  In 
contrast, eGFP without any NLS tag was homogeneously distributed in the nucleus and cytosol 













Figure 5.4. Viability of HeLa cells at different concentrations of NPSC-NLSc-Myc -eGFP complexes 
measured by Alamar Blue assay. 
 
 





Figure 5.6. Typical results of quantitative fluorescence intensity analyses of NLS-eGFPs in single 
cells. Quartiles of pixel intensities were illustrated as box plots. 
 
Figure 5.7. LSCM image showing cellular distribution pattern of eGFP without NLS.  Bar: 20 µm. 
 
We next tracked the dynamics of the nuclear accumulation of the NLS-eGFP in the cell 
through live cell video imaging. Since NLSc-Myc-eGFP displayed maximal nuclear accumulation 
ability, we chose NLSc-Myc-eGFP for these studies. Fluorescence imaging showed substantial 
accumulation of NLSc-Myc-eGFP occurred in the nucleus within 60s of cytosolic delivery (Figure 
5.8a). Time-lapse LSCM images at minute scale unveiled the kinetics of nuclear import of NLSc-Myc-
eGFP, as shown in Figure 5.8b. NLSc-Myc-eGFP was delivered into the cytosol, with importation to 
the nucleus occurring immediately. (Figure 5.9). Within 6 min, nuclear import reached equilibrium 
(Figure 5.8c). This result is similar to previous measurement of in vitro nuclear protein import 
using permeabilized cells, in which half-saturation time ranges from 1.3 to 13.9 min.20  As 
expected from the active transport process employed by the cell,4 depletion of cellular ATP by 
NaN3 and 2-deoxyglucose (DOG) resulted in no nuclear localization (Figure 5.8d), resembling the 
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distribution of the normal eGFP without NLS (Figure 5.10). Notably, delivery of NLSc-Myc-eGFP to 
the cytosol was not disrupted by ATP depletion, indicating non-endocytic pathway involved in the 
delivery. This result was in agreement with our previous findings.  
 
Figure 5.8. Nuclear import of eGFP fused with NLS is rapid and ATP dependent. (a) Time-lapse 
fluorescent microscopic images show nuclear accumulation of NLSc-Myc-eGFP starts within 1 
minute after presenting in cytosol. (b,c) Time-lapse LSCM images unveil the kinetics of nuclear 
import of NLSc-Myc-eGFP. (d) No nuclear accumulation of NLSc-Myc-eGFP is observed after the 
delivery following ATP depletion in the presence of 3 mg/mL NaN3 and 50 mM 2-deoxyglucose. 




Figure 5.9. Typical results of quantitative fluorescence intensity analyses of NLSc-Myc-eGFPs in 





Figure 5.10. A comparison between the cytosolic delivery of (a) NLSc-Myc-eGFP at ATP depletion 
condition and (b) eGFP without NLS into HeLa cells. Bars: 20 µm. (c,d) Quartiles of pixel 
intensities were illustrated as box plots. For (d) Analysis of the boxed cell in b. 
 
5.3 Methods 
5.3.1 Construction of plasmids and Escherichia coli strains 
6xHis-eGFP expression vector (pET21d-eGFP) was obtained from Novagen. Briefly, using 
6xHis-eGFP as the template, PCR was performed with primers listed in the Table 5.3. 
Subsequently, PCR products were digested using BamHI and HindIII restriction enzymes and 
inserted into pQE80 vector, downstream of nucleotides for six histidine tag to construct pQE80-
6xHis-NLS-eGFP or pQE80-6xHis-eGFP-NLS expression vectors. Successful cloning was confirmed 





Table 5.3. Primers for PCR cloning 



































 Reverse 5’-TATAAAGCTTTTACTTGTACAGCTC-3’ 
 
5.3.2 Protein Expression 
To produce recombinant proteins, plasmids carrying 6xHis-NLS-eGFP or 6xHis-eGFP-NLS 
were transformed into Escherichia coli BL21 (DE3) strain. A transformed colony was picked up to 
grow small cultures in 50 mL 2XYT media at 37°C overnight. The following day, 15 mL of grown 
culture was inoculated into 1 L 2XYT media and allowed to grow at 37°C until OD reaches 0.6. At 
this point, the protein expression was induced by adding isopropyl-β-D-thiogalactopyranoside 
(IPTG; 1 mM final concentration) at 25°C. After 16 hours of induction, the cells were harvested 
and the pellets were lysed using a microfluidizer. His-tagged fluorescent proteins were purified 
from the lysed supernatant using His-Pur cobalt columns. The integrity and the purity of native 
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protein were determined by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Figure 5.2 shows the SDS-PAGE gel of the purified proteins. 
5.3.3 Protein-NPSC Complex Formation 
HKRK gold nanoparticles (HKRK AuNPs) were synthesized according to a previous report.10 
To make the NLS-eGFP-NPSC complex, 2.5 μM HKRK AuNPs were incubated with 1 μM eGFP in 30 
μL of phosphate buffer (5 mM, pH = 7.4) for 10 min. Then, 1 μL of linoleic acid was mixed with 500 
μL of phosphate buffer (5 mM, pH = 7.4) containing 1 μM HKRK AuNPs and agitated by an 
amalgamator (Yinya New Materials Co. Ltd, Hangzhou, China) at 5000 rpm for 100 s to form 
emulsions. Finally, the mixture of the protein and HKRK AuNPs was diluted to 45 μL with 
phosphate buffer (5 mM, pH = 7.4) followed by the addition of 5 μL of the emulsion. The NLS-
eGFP-NPSC complexes were ready to use after 10 min incubation at room temperature. The final 
concentrations of HKRK AuNPs and eGFP were 1.5 μM and 600 nM, respectively. 
5.3.4 Cell viability assay (Alamar Blue) 
15,000 HeLa cells were cultured in a 96-well plate for 24 h prior to the experiment. The 
cells were washed by cold phosphate buffer saline (PBS) 3 times before the delivery, then different 
amounts of the eGFP-NPSC complex (prepared as mentioned above) were diluted by DMEM and 
incubated with the cells for 1 h followed by the incubation with DMEM containing 10% FBS and 
1% antibiotics for 23 h. After washing with PBS 3 times, the cells were then incubated with 200 μL 
DMEM containing 10% Alamar Blue for 3 h. Cell viability was calculated by measuring the 
fluorescence intensity of Alamar Blue at 590 nm, with an excitation of 535 nm. 
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5.3.5 Cell culture 
HeLa cells were cultured in a humidified atmosphere (5% CO2) at 37°C and grown in 
Dulbecco’s modified eagle’s medium (DMEM, low glucose) supplemented with 10% fetal bovine 
serum (FBS) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). 
5.3.6 NLS-eGFP Delivery 
A total of 60,000 or 240,000 HeLa cells were cultured in a 24-well plate or confocal dish, 
respectively, for 24 h prior to delivery. The cells were washed by cold phosphate buffer saline 
(PBS) three times right before delivery. After the preparation of cells, NLS-eGFP-NPSC complex 
solution (50 or 150 μL of the NLS-eGFP-NPSC complex diluted by 450 μL or 1.35 mL of the DMEM 
without FBS, respectively) was incubated with the cells for 1 h in a 24-well plate or confocal dish, 
followed by incubation with fresh DMEM with 10% FBS for 1 h unless otherwise mentioned.  
5.3.7 Cell Imaging 
240,000 HeLa cells were cultured in the confocal dish for 24 h prior to the experiment. 
Before imaging, cells were washed by PBS for three times followed by the incubation with NLS-
eGFP-NPSC in cell culture media. The cells were then observed by LSCM (LSM 510, Zeiss, Germany) 
microscope. 
5.3.8 Live Cell Imaging 
240,000 HeLa cells were cultured in the confocal dish for 24 h prior to delivery. Before 
imaging, cell culture media were replaced PBS with 10% FBS to eliminate the fluorescence of 
media. The confocal dish was then placed in the live cell imaging chamber with 5% CO2 and at 
37°C on the fluorescent (IX51, Olympus, Japan) or LSCM (LSM 510, Zeiss, Germany) microscope. 
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A series of images were taken at 4 s interval on fluorescent microscope or 1 min interval on LSCM 
microscope. 
5.3.9 ATP Depletion 
Cells were treated with cell culture media containing 3 mg/mL NaN3/50 mM 2-
deoxyglucose 1 h prior to delivery. NLS-eGFP was then delivered using the same method 
mentioned above. However, during the delivery, 3 mg/mL NaN3 and 50 mM 2-deoxyglucose were 
supplemented in the media to maintain the ATP depleted status of cells.  
5.3.10 Image Analysis 
Images obtained from LSCM were in 8-bit grayscale format containing both fluorescent 
and bright field channels. The fluorescent channel was extracted by ImageJ. The pixel intensity 
profile along line segment was also performed by ImageJ. The cytosol and nucleus of each cell 
were separated by Photoshop and saved as 8-bit grayscale Tiff files with black backgound without 
any intensity adjustment. The resulted images were processed and plotted by R. 
5.4 Conclusion 
In summary, we have developed an effective, straightforward and non-invasive method 
for quantitative monitoring of intracellular trafficking of proteins. We demonstrated the efficacy 
of this method using NLS-mediated nuclear delivery, however, this strategy can be readily 
generalized to other trafficking processes, providing a new tool for probing the dynamics of 
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EFFECTIVE NUCLEAR LOCALIZATION OF PROTEINS WITH BORONATE TARGETING SIGNALS 
6.1 Introduction 
The localization of proteins to proper subcellular positions is essential for their function.1 
This targeting process relies on specific signals that interact with sorting factors and/or organelle 
receptors to guide proteins to their final destination.2 Taking advantage of such cellular 
distribution systems, proteins have been engineered for intracellular targeting and drug delivery.3 
As many drug targets are localized to particular subcellular compartments, these intracellularly-
targeted therapeutic strategies significantly reduce side effects while increasing drug efficacy.4  
The development of intracellular targeting systems is, however, currently limited to a set 
of known peptide localization signals.5 By mimicking biological pathways, synthetic systems 
provide an alternative strategy for intracellular targeting that offers more versatility for drug 
development and biological research. Synthetic targeting elements would also sidestep the 
challenges of fusing natural signaling peptides to proteins by genetic engineering, where many 
proteins are difficult to express recombinantly, or adopt distorted conformations in foreign hosts.  
Currently, there are few non-peptidic signals suitable for subcellular localization of 
biomacromolecules. The one widely recognized example is the triphenylphosphonium (TPP) 
group. TPP conjugates are used for both mitochondrial labeling and targeted delivery driven by 
large mitochondrial membrane potential, and not through active transport.6 However, synthetic 
targeting to other organelles through either active or passive means are currently unavailable.  
There are two key challenges for developing synthetic signals for subcellular localization 
of proteins in live cells: cytosolic access7 and targeting efficiency.8 Previously, we have developed 
an HKRK nanoparticle stabilized capsule (NPSC) platform for cytosolic delivery of negatively 
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charged proteins9, 10 and an aromatic boronic acid (4-nitrophenyl 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl carbonate; NBC) tag for facile protein modification.11 Herein, we report 
that the NBC tag directs proteins to the nucleus after cytosolic delivery using an NPSC system with 
low toxicity (Figure 6.1 and Figure 6.2). This is, to our knowledge, the first fully synthetic nuclear 
localization signal to be described. Proteins modified with this nuclear NBC label, including 
ribonuclease A (RNase A) and fluorescent proteins, were rapidly delivered into cells using NPSCs 
and significantly accumulated in nuclei. Similar to its various natural counterparts, NBC-mediated 
nuclear import is governed by importin α/β, with passive adsorption directed by the aromatic 
moiety also contributing to the nuclear accumulation. Numerous important cellular processes, 
with their associated drug targets, localize to the nucleus. Developing synthetic signals for protein 
nuclear localization not only charts an alternative pathway for biochemical research, but also 
holds great promise for designing better therapeutic strategies.4  
 
Figure 6.1. Schematic diagram showing delivery of RNase A-NBC-NPSC complex to the cytosol and 
into the nucleus of cells. 
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Figure 6.2. Viability of HeLa cells at different concentrations of NPSC measured by Alamar Blue 
assay. 
6.2 Methods 
6.2.1 GFP expression 
To produce recombinant proteins, a plasmid carrying 6xHis-eGFP was transformed into 
the Escherichia coli BL21 (DE3) strain. A transformed colony was picked up to grow small cultures 
in 50 mL 2XYT media at 37°C overnight. The following day, 15 mL of grown culture was inoculated 
into one liter of 2XYT media and allowed to grow at 37°C until OD reaches 0.6. At this point, the 
protein expression was induced by adding isopropyl-b-D-thiogalactopyranoside (IPTG; 1 mM final 
concentration) at 25°C. After 16 hours of induction, the cells were harvested and the pellets were 
lysed using a microfluidizer. His-tagged fluorescent proteins were purified from the lysed 
supernatant using His-Pur cobalt columns. 
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6.2.2 Protein modification 
Fluorescent FITC-labeled RNase A-NBC was described previously.11 EGFP-NBC or EGFP-NC 
were prepared by reacting eGFP with an excess amount of NBC or NC according to our previous 
report.11 Briefly, 1.3 mg/mL eGFP (in 0.1 M NaHCO3 buffer solution, pH = 8.5, 0.72 mg protein in 
total) was mixed with 150 µL DMSO solution containing 0.25 mg NBC or NC. The reaction mixtures 
were then stirred at room temperature for an additional 10 h with protection from light, followed 
by ultrafiltration purification using Amicon® Ultra Centrifugal Filters (MWCO = 10,000, Millipore, 
MA). EGFP-CPB was prepared by mixing eGFP with N-hydroxysuccinimide (NHS)-activated 4-
carboxyphenyl-boronic acid (CPB) in a similar way to that of eGFP-NBC modification. The NHS 
ester of CPB was prepared by adding N-hydroxysuccinimide (0.23 mg, 1.98 μmol), EDC (0.38 mg, 
1.98 μmol), DMAP (0.046 mg, 0.38 μmol) into a DMSO solution of 4-carboxyphenylboronic acid 
(0.32 mg, 1.89 μmol), followed by an additional 12 h of incubation before mixing with eGFP. The 
protein molecular weight was determined using MALDI-TOF mass spectrometry. Proteins labeled 
with three NBC tags were used in this research (data shown in Figure 6.3 and 6.9). The tetramer 
structure of dsRed with NBC tag was confirmed by denaturing (monomer) and semi-denaturing 
(tetramer) SDS-PAGE analysis. For denaturing SDS-PAGE analysis, protein samples were mixed 
with 5x sample buffer including 5% 2-mercaptoethanol and heated at 95 °C for 5 min prior to 
loading. For semi-denaturing condition, protein samples were directed loaded after mixing with 
5x sample buffer without 2-mercaptoethanol or heating. 
6.2.3 Protein-NPSC Complex Formation 
HKRK gold nanoparticles (HKRK AuNPs) were synthesized according to a previous report.9 
To make the protein-NPSC complex, 2.5 μM HKRK AuNPs were incubated with 1.5 μM of protein 
in 60 μL of phosphate buffer (5 mM, pH = 7.4) for 10 min. Then, 1 μL of linoleic acid was mixed 
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with 500 μL of phosphate buffer (5 mM, pH = 7.4) containing 1 μM HKRK AuNPs and agitated by 
an amalgamator (Yinya New Materials Co. Ltd, Hangzhou, China) at 5000 rpm for 100 s to form 
emulsions. Finally, the mixture of the protein and HKRK AuNPs was diluted to 135 μL with 
phosphate buffer (5 mM, pH = 7.4) followed by the addition of 15 μL of the emulsion. The protein-
NPSC complexes were ready to use after 10 min of incubation at room temperature. The final 
concentrations of HKRK AuNPs and the protein were 1.5 μM Figure 6.300 nM, respectively. The 
preparation procedure of Arginine AuNP NPSCs is the same expect the use of Arginine AuNPs 
instead of HKRK AuNPs. 
6.2.4 Cell culture 
HeLa cells were cultured in a humidified atmosphere (5% CO2) at 37°C and grown in 
Dulbecco’s modified eagle’s medium (DMEM, low glucose) supplemented with 10% fetal bovine 
serum (FBS) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). 
6.2.5 Cell synchronization 
For G0/G1 phase arrest, HeLa cells were cultured in DMEM without FBS for 72 hr prior to 
the experiment. For S phase synchronization, HeLa cells were arrested in DMEM with 2 mM 
thymidine for 17 hr, then released by culture in DMEM without thymidine. After that, cells were 
arrested again in DMEM with 2 mM thymidine for 17 hr. Before flow cytometry, cells were 
trypsinized, fixed with 66% ethanol for 2 hr and stained with propidium iodide (PI) in the presence 
of RNase A. 
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6.2.6 Cell viability assay (Alamar Blue) 
15,000 HeLa cells were cultured in a 96-well plate for 24 hr prior to the experiment. The 
cells were washed by cold phosphate buffer saline (PBS) three times before the delivery, then 
different amounts of the NPSC complex (prepared as mentioned above) were diluted by DMEM 
and incubated with the cells for 1 hr followed by the incubation with DMEM containing 10% FBS 
and 1% antibiotics for 23 hr. After washing with PBS three times, the cells were then incubated 
with 200 μL DMEM containing 10% Alamar Blue for 3 h. Cell viability was calculated by measuring 
the fluorescence intensity of Alamar Blue at 590 nm, with an excitation of 535 nm. 
6.2.7 Protein delivery 
A total of 240,000 cells were cultured in a confocal dish for 24 hr prior to delivery. The 
cells were washed in cold phosphate buffer saline (PBS) thrice right before delivery. After 
preparation, the cells were incubated in protein-NBC-NPSC complex solution (150 μL of the 
complex diluted by 1.35 mL of the DMEM without FBS) for 1 hr, followed by incubation with fresh 
DMEM with 10% FBS for 10 min, unless otherwise mentioned. The cells were then kept in PBS and 
imaged in a LSCM (LSM 510, Zeiss, Germany or Nikon Ti, Japan) microscope. For flow cytometry 
analysis, cells were washed by PBS for three times and collected after trypsinization. 
6.2.8 Importin α/β inhibition 
Cells were treated with cell culture media containing 25 µM ivermectin 1 hr prior to 
delivery. The protein was then delivered using the same method mentioned above. During the 
delivery, 25 µM ivermectin were supplemented to the media to maintain the Importin α/β 
inhibition status of cells. The inhibition condition was kept during imaging. 
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6.2.10 ATP Depletion 
Cells were treated with cell culture media containing 3 mg/mL of NaN3/50 mM 2-
deoxyglucose 30 min prior to delivery. The protein was then delivered using the same method 
mentioned above. During the delivery, 3 mg/mL NaN3 and 50 mM 2-deoxyglucose were 
supplemented to the media to maintain the ATP depleted status of the cells. The ATP depletion 
condition was kept during imaging. 
6.2.11 Image Analysis 
Images obtained with the LSCM were in 8-bit grayscale format. The fluorescent channel 
was extracted by ImageJ. The background, cytosol, nucleus and nuclear granules (if any) of each 
cell were separated by Photoshop and saved as 8-bit grayscale Tiff files without any intensity 
adjustment. The resulted images were processed and plotted by R. Six individual cells were 
analyzed in each group. 
6.3 Results 
6.3.1 RNase A-NBC accumulates in the nucleus after NPSC delivery 
RNase A and its homologues have therapeutic implications for various diseases, such as 
cancer12 and AIDS.13 Delivery of RNase A and its homologues into cells, and especially into the 
nucleus, results in intracellular RNA degradation, thus compromising cell function and viability.14 
To determine the cellular behavior of the NBC tag, we conjugated fluorescein isothiocyanate 
(FITC) to RNase A-NBC (Figure 6.3). Consistent with our previous reports,9, 15 NPSCs containing 
FITC labeled RNase A-NBC were readily formed and delivered into HeLa cells (Figure 6.3b). RNase 
A-NBC that was released into the cytosol was imaged by laser scanning confocal microscopy 
(LSCM). One hour after delivery RNase A-NBC was strongly accumulated in the nucleus (Figure 
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6.4a and Figure 6.5). Within the nucleus, RNase-A-NBC further accumulated into granule-like 
structures (indicated by arrows in Figure 6.4a) that were distinct from the nucleoplasm. In 
comparison, RNase A conjugated with cis-aconitic acid (ACO tag; structure shown in Figure 6.5) 
revealed only limited nuclear enrichment after cytosolic delivery (Figure 6.5), with the same 
fluorescent granular structure inside nucleus as the NBC-tagged system. This result indicates that 
RNase A is capable of accessing nucleus due to its small size16 and can be retained there with 
intranuclear structures or substrates. However, in the presence of NBC tag, the accumulation of 
RNase A in the nucleus dramatically increased. Noting that this delivery is based on 
supramolecular interactions, a few extracellular aggregates can be observed due to instability of 
a small portion of delivery vehicles.17, 18 
 
Figure 6.3. Delivery complex of RNase A-NBC labeled with FITC and NPSCs. (a) Mass 
spectrometry of RNase A-NBC labeled with FITC. (b) Dynamics light scattering results of the size 





Figure 6.4. Delivery of RNase A-NBC into HeLa cells using the NPSC delivery platform.  (a) LSCM 
image showing RNase A-NBC delivery into HeLa cells by NPSCs. Arrows indicate granular 
structures of RNase A-NBC formed in the nucleus. (b) Quantitative analysis of fluorescence 
intensities in a. (c) Colocalization of RNase A-NBC with Hoechst 33342, a DNA staining dye. (d) 
Colocalization of RNase A-NBC with Pyronin Y, a dsRNA staining dye. Scale bars: 10 µm. 
 
 
Figure 6.5. LSCM image showing RNase A delivery into HeLa cells by NPSCs: (a) RNase A-NBC and 




Quantitative analysis (Figure 6.6) of LSCM images revealed that the fluorescence intensity 
of RNase A-NBC in the nucleoplasm was 490% ± 94% higher than in the cytosol. The intensity of 
RNase A-NBC fluorescence in the nuclear granules was 2300% ± 730% higher than in the cytosol 
(Figure 6.4b and Table 6.1). In contrast, the intensity of RNase A-ACO in the nucleus was only 
130% ± 30% higher than in the cytosol (Table 6.2). Although RNase A is a small protein and might 
naturally penetrate into the nucleus in the presence of NBC tag, the concentration increase of 
RNase A in the nucleus is almost four-fold higher than that of the control group, indicating efficient 
targeting to the nucleus. 
 
Figure 6.6. Quantitative analysis of an individual cell in Figure 1b after RNase A-NBC delivery. (a) 
Analysis result after R processing. (b) Different parts of the image were split for the analysis. 
Table 6.1. Quantitative analysis of individual cells after RNase A-NBC delivery. 
 Absolute median intensity of one cell  Enhanced fluorescence intensity (%) 
 Background Cytosol Nucleus Granules  Nucleus:Cytosol Granules:Cytosol 
1 15 20 44 130  480 2200 
2 15 21 58 212  617 3183 
3 14 17 27 94  333 2567 
4 13 20 57 210  529 2714 
5 18 28 80 215  520 1870 
6 16 32 108 211  461 1085 
    Average  490 2300 
    SD  94 730 
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Absolute median intensities were obtained from R.  
The percentage of enhanced fluorescence intensity was calculated using the following 
equations: 
Nucleus% = [(Inu – Ibk)/(Icyto – Ibk) – 1] x 100% 
Granule% = [(Igr– Ibk)/(Inu – Ibk) – 1] x 100% 
Where Nucleus% corresponds to the percentage of enhanced fluorescence intensity in the 
nucleus when compared to the cytosol, and Granule% in the nuclear granules when compared 
to the nucleus. Ibk is the median fluorescence of the background. Icyto is the median fluorescence 
of the cytosol. Inu is the median fluorescence of the nucleus. Igr is the median fluorescence of 
nuclear granules. 
 
Table 6.2. Quantitative analyses of individual cells after RNase A-ACO delivery 




 Background Cytosol Nucleus 
1 17 41 70 121 
2 17 34 61 159 
3 17 30 44 108 
4 17 35 56 117 
5 17 33 52 119 
6 17 36 71 184 
   Average 135 
   SD 30 
 
We next determined the subnuclear localization of the RNase A-NBC. After RNase A-NBC 
delivery we stained the cells with either Hoechst 33342 (Figure 6.4c), a blue fluorescent dye for 
DNA staining, or Pyronin Y, a red fluorescent dye specific for visualizing double stranded RNA 
(Figure 6.4d). The Hoechst 33342 experiments revealed that RNase A-NBC distributed throughout 
the nucleoplasm and nucleolus (Figure 6.4c). The Pyronin Y experiments, however, clearly showed 
that the RNase A-NBC nuclear granules co-localize with condensed nuclear RNAs (Figure 6.4d and 
Figure 6.7). A number of nuclear RNAs, including rRNA and mRNA, are stored in nucleoli, 




Figure 6.7. Z-stack overlap of RNase A-NBC with Pyronin Y. Green: RNase A-NBc; Red: Pyronin Y. 
Scale bar: 20 µm. 
6.3.2 NBC tag drives nuclear accumulation 
Although RNase A-NBC showed an obvious nuclear accumulation, its natural ability to be 
enriched in the nucleus complicated our analysis. We removed these possibilities by conjugating 
the NBC tag to eGFP (eGFP-NBC; Figure 6.8a and Figure 6.9). EGFP was chosen for two reasons: (i) 
The fluorescence of eGFP depends on the conformation and integrity of the protein; structural 
change or degradation of eGFP therefore results in substantial fluorescence loss;19 (ii) EGFP does 




Figure 6.8. Nuclear accumulation of eGFP relies on the NBC label. (a) LSCM image of a HeLa cell 
after the delivery of eGFP-NBC. (b) LSCM image of a HeLa cell after the delivery of eGFP-CPB. (c) 
LSCM image of a HeLa cell after the delivery of eGFP-NC. (d) LSCM image of a HeLa cell after the 
delivery of normal eGFP. Scale bars: 20 µm. (e) Quantitative analysis of the increased 
fluorescence intensity of eGFP in the nucleus. Six random cells representing different intensities 





Figure 6.9. Mass spectrometry of both native and tagged GFP.  
 
As expected, eGFP without NBC tag is homogeneously distributed by the NPSC platform 
throughout the cell, including the nucleus (Figure 6.8d). One hour after delivery, however, eGFP-
NBC was highly localized in the nucleus, similarly to RNase A-NBC (Figure 6.8a and Figure 6.10). 
Quantitative analysis of the LSCM image revealed that the average concentration of eGFP-NBC 
was 300% ± 50% higher in the nucleus than in the cytosol (Figure 6.11a and Table 6.3). In our 
previous study, we have compared the nuclear localization efficiencies of a series of nuclear 
localization signals.21 The signal derived from c-Myc protein revealed highest efficiency. However, 
the efficiency of the NBC tag is almost two-fold to that of c-Myc signal investigated on the same 
delivery platform and with the same protein. Nonetheless, eGFP-NBC was not concentrated in 
nucleoli or nuclear granules (Figure 6.12). This difference in localization between eGFP-NBC and 
RNase A-NBC is likely to result from their distinct functional activities. RNase A is an enzyme 
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specifically targeting RNA, and might therefore become enriched by its substrate after accessing 
the nucleus. On the other hand, eGFP is a fluorescent protein without other known cellular 
function.  
 
Figure 6.10. Large scale LSCM images of HeLa cells after delivery of GFP with different labels. 
Native GFP was delivered as a control. Scale bars: 20 µm. 
 
 
Figure 6.11. Quantitative analysis of individual cells in Figure 6.8. 
 
Table 6.3. Quantitative analyses of individual cells after GFP-NBC delivery 
 




  Background Cytosol Nucleus 
1 19 30 53 209 
2 23 67 191 282 
3 23 40 89 288 
4 18 57 173 297 
5 18 29 68 355 
6 21 32 70 345 
      Average 300 






Figure 6.12. GFP-NBC dose not accumulate into nucleoli of the HeLa cell. Scale bars: 20 µm. 
 
We next performed preliminary structure-activity studies to identify the features of NBC 
conjugation that facilitate nuclear targeting of proteins. In addition to the NBC tag, 4-
carboxyphenylboronic acid (CPB, Figure 6.8b and Figure 6.9) and benzyl 4-nitrophenyl carbonate 
(NC, Figure 6.8c and Figure 6.9) were conjugated to eGFP. CPB is similar in structure to the NBC 
tag, but is somewhat more electron deficient due to the amide moiety. With its lack of boronate 
functionality, NC allowed for the evaluation of the role of the aromatic group in nuclear targeting.  
LSCM images showed enhanced nuclear accumulation of both CPB and NC conjugates, 
albeit with lower efficiency than observed with NBC. The intensity of eGFP in the nucleus relative 
to the cytosol was 140% ± 40% higher for eGFP-CPB, (Figure 6.11b and Table 6.4), and 60% ± 20% 
higher for eGFP-NC (Figure 6.11c and Table 6.5). Statistical analyses confirmed that there is a 
significant difference in nuclear accumulation between eGFP-NBC, eGFP-CPB and eGFP-NC (P < 
0.01; Figure 6.8e). Moreover, eGFP tagged with NBC, CPB or NC has significantly stronger nuclear 
accumulation when compared to native eGFP (Figure 6.8d, Figure 6.11d and Table 6), as measured 
by eGFP fluorescence intensity (P < 0.01; Figure 6.8e). Flow cytometry analysis (Figure 6.13) 
revealed that successful GFP delivery occurred in 70% to 90% of the cells in all delivery groups. 
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Furthermore, the decrease of average fluorescence intensity of cells (Figure 6.13c) is associated 
with the increase of nuclear condensation of GFP. This decrease is presumably due to the 
localization of GFP that inhibits the fluorescence emission. These results show that the boronate 
and the aromatic moieties contribute synergistically to nuclear localization. In addition, although 
boronate can covalently bind with glycoproteins at high pH, this reaction is not favored under 
physiological condition and is hence not expected to inhibit the nuclear import of tagged 
proteins.22  
Table 6.4. Quantitative analysis of individual cells after GFP-CPB delivery 
 




 Background Cytosol Nucleus 
1 16 49 106 173 
2 16 73 163 158 
3 19 47 94 168 
4 14 57 98 95 
5 14 39 57 72 
6 16 72 155 148 
   Average 140 
   SD 40 
 
Table 6.5. Quantitative analysis of individual cells after GFP-NC delivery 
 




 Background Cytosol Nucleus 
1 17 69 118 94 
2 21 92 148 79 
3 19 56 75 51 
4 25 111 139 33 
5 24 44 52 40 
6 31 143 213 63 
   Average 60 




Table 6.6. Quantitative analysis of individual cells after GFP delivery 
 




 Background Cytosol Nucleus 
1 23 128 125 -2.9 
2 22 43 45 9.5 
3 25 106 108 2.5 
4 23 127 137 9.6 
5 22 58 65 19.4 
6 22 84 82 -3.2 
   Average 6 























Figure 6.13. Flow cytometry results of GFP delivery with or with without tags to HeLa cells. (a) 
Flow cytometry data. (b) Ratio of GFP positive cells in each group. (c) Average fluorescence 
intensity of cells in each group. 
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Proteins with molecular weight greater than 60 kD cannot passively diffuse into the 
nucleus, making large proteins excellent testbeds for demonstrating active transport. To 
demonstrate whether active import is involved in the nuclear localization of proteins mediated 
by our NBC ligand, we employed dsRed, a tetramer fluorescent protein with the molecular weight 
of 112 kD (Figure 6.14a and b). DsRed has been shown to access the nucleus only in the presence 
of nuclear localization signals.23 After 1 hr delivery, dsRed labeled with NBC tag (dsRed-NBC) was 
strongly accumulated in nucleus (Figure 6.15a and Figure 6.14c). In contrast, dsRed without NBC 
tag did not enter nucleus due to its large size (Figure 6.15b and Figure 6.14d).  After 8 hr culture, 
obvious nuclear localization of dsRed-NBC in HeLa cell with was still observed (Figure 6.15c). 






























Figure 6.14. Delivery of dsRed with or without NBC tag to HeLa cells. (a) SDS-PAGE gel of dsRed 
before Brilliant Blue staining. (b) SDS-PAGE gel after Brilliant Blue staining. Under denaturing 
condition to break the tetramer structure, samples were denatured with 2-mercaptoethanol at 
95 °C for 5 min. Under semi-denaturing condition to keep the tetramer structure, samples were 
loaded without treatment of 2-mercaptoethanol or heating. Protein amount for each lane: 20 
µg. (c) Large scale LSCM images of HeLa cells after 1 hr delivery of dsRed with NBC tag. (d) Large 









Figure 6.15. Large fluorescent protein dsRed was accumulated in nucleus after labeling with NBC 
tag. (a) deRed-NBC accessed nucleus of HeLa cell after 1 hr delivery. (b) dsRed without NBC tag 
did not enter nucleus of HeLa cell after 1 hr delivery. (c) 8 hr after dsRed-NBC delivery to HeLa 
cells. Scale bars: 20 µm. 
6.3.3 NBC mediated nuclear localization is independent of cell synchronization, cell type, 
delivery vehicle and protein size 
To analyze whether nuclear localization of eGFP-NBC is cell cycle dependent, we 
synchronized HeLa cells to G0/G1 phase by serum starvation for 72 hr or to the beginning of S 
phase by double thymidine block prior to delivery (Figure 6.16). After 1 hr delivery, we observed 
that eGFP-NBC accumulated in nuclei of cells regardless of cell phase (Figure 6.17a, b). This result 




Figure 6.16. Flow cytometry after cell synchronizations. 
 
 
Figure 6.17. NBC mediated nuclear localization is independent of cell synchronization, cell type 
and delivery vehicle. (a) eGFP-NBC delivery after cells being synchronized to G0/G1 phase and 
(b) to the beginning of S phase. (c) eGFP-NBC delivery to human mesenchymal stem cell. (d) 




We next determined the behavior of NBC tag in human mesenchymal stem cells (MSC), a 
cell type with high potential in clinical use that is often prepared for use ex vivo. As expected, 
obvious nuclear accumulation of eGFP-NBC was observed after 1 hr delivery (Figure 6.17c and 
Figure 6.18). MSC is important for tissue engineering and disease therapy,24 therefore, delivery of 




Figure 6.18. Large scale LSCM images of MSCs after delivery of GFP tagged with NBC. Scale bar: 
20 µm. 
 
Since HKRK peptide resembles the structure of SV40 nuclear localization signal 
(PKKKRKV),25 we wanted to eliminate the possibility that HKRK ligand on AuNP surface helped 
nuclear localization of proteins, even though eGFP without NBC tag was not enriched in nucleus 
(Figure 6.8d). Previously, we have developed an arginine-terminated AuNP based NPSC system 
for the cytosolic delivery of siRNA.15 Although this platform is not optimized for proteins, certain 
proteins can still be delivered to cell cytosol. Using this platform, we completely ruled out the 
possible function of HKRK peptide in nuclear localization of proteins. As shown in Figure 6.17d, 
after 1 hr delivery, eGFP-NBC efficientlyy accumulated in nucleus, similar to that delivered by 
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HKRK NPSCs. This result further confirmed that the nuclear localization of proteins is due to the 
NBC tag, not the delivery vehicle. 
6.3.4 Pathways involved in NBC nuclear accumulation 
Nuclear accumulation of proteins can be mediated by either active import or passive 
diffusion.26 We first treated HeLa cells with ivermectin,27 a specific inhibitor of the importin α/β 
pathway to assess active transport. Nuclear localization of eGFP-NBC was still observed after 
ivermectin treatment, (Figure 6.19a, b) however the enhancement of nuclear localization 
decreased dramatically to 60% ± 30% (Figure 6.19e, Figure 6.20a and Table 7). This result indicates 
that active transport through the importin α/β pathway is responsible for the majority of the 
nuclear localization observed with NBC tagged proteins. To test whether other active import 
pathways are involved in the nuclear accumulation of eGFP-NBC, we depleted ATP from HeLa cells 
before and during delivery. ATP is a prerequisite for both importin-dependent28 and other29 
pathways. One hour after delivery in the ATP depleted condition, nuclear accumulation was 
observed (Figure 6.19c). Fluorescence intensity enhancement in the nucleus was 95% ± 20% 
(Figure 6.19g, Figure 6.20b and Table 8), similar to that achieved after ivermectin treatment, 




Figure 6.19. Inhibition of active import to nucleus significantly reduces nuclear accumulation of 
NBC-tagged eGFP. (a) eGFP-NBC delivery before and (b) after inhibition of importin α/β 
pathway. (c) eGFP-NBC delivery after inhibition of all active import pathway by ATP depletion. 
(d) eGFP-NC delivery before and (e) after inhibition of importin α/β pathway. (f) eGFP-NC 
delivery after inhibition of all active import pathway by ATP depletion. Scale bars: 20 µm. (g) 
Quantitative analysis of increased fluorescence intensity of eGFP-NBC and eGFP-NC in the 
nucleus after delivery with or without pretreatment using six cells in each group. 
Table 6.7. Quantitative analysis of individual cells after GFP-NBC delivery in the presence of 
ivermectin. 
 




 Background Cytosol Nucleus 
1 20 39 53 74 
2 17 32 41 60 
3 16 40 52 50 
4 15 30 46 107 
5 17 32 35 20 
6 16 44 58 50 
   Average 60 





Figure 6.20. Quantitative analyses of individual cells in Figure 6.19. 
 
Table 6.8. Quantitative analysis of individual cells after GFP-NBC delivery with ATP depletion. 
 




 Background Cytosol Nucleus 
1 15 36 50 67 
2 15 27 37 83 
3 16 33 49 94 
4 16 32 47 94 
5 17 94 193 129 
6 17 39 62 105 
   Average 95 
   SD 20 
 
Significant (and similar) nuclear localization was observed when importin was inhibited 
and from the non-boronate NC system, suggesting a passive mechanism dependent on the 
aromatic substitution. To test this hypothesis, we delivered eGFP-NC into HeLa cells either in the 
presence of ivermectin (Figure 6.19d, e) or under ATP depletion (Figure 6.19f). As expected, 
nuclear accumulation of eGFP-NC was observed in both conditions. Compared to eGFP-NBC 
delivery, there was no substantial difference between eGFP-NC delivery with or without either 
pretreatment (Figure 6.19g, Figure 6.20c, d and Tables 6.9, 6.10). These results corroborate our 
observation that the benzene ring is involved in nuclear accumulation, with localization 
 
117 
potentially arising from hydrophobic interactions mediated by aromatic substituents. While 
aromatic rings naturally exist in some amino acids, they are usually not presented on the exposed 
outer surface of proteins. In contrast, NBC and NC tags are directly conjugated to the protein 
surface11 enabling hydrophobic interactions with the contents of nucleus, in analogy with passive 
nuclear localization during viral infection.30  
Table 6.9. Quantitative analysis of individual cells after GFP-NC delivery in the presence of 
ivermectin. 
 




 Background Cytosol Nucleus 
1 20 72 121 94 
2 17 51 87 106 
3 16 56 80 60 
4 15 32 46 82 
5 16 39 66 117 
6 17 35 45 56 
   Average 85 
   SD 25 
 
6.4 Discussion 
As discussed previously, RNase A-NBC has only a slight activity decrease compared to 
native RNase A.11 In our current study study, we did not observe obvious structural damage or 
activity loss of fluorescent proteins after conjugation with NBC tag. Furthermore, the tag can be 
designed as permanent or cleavable under certain stimuli.11 We expect that a permanent tag can 
be used for irreversible nuclear import of proteins and a cleavable tag may be applied in case 
reversible nuclear import of proteins is desired.   
Our inhibition study demonstrated that after cytosolic release nuclear accumulation of 
NBC tagged proteins occurs via two distinct mechanisms: (i) Active transportation into the nucleus 
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via interaction between boronic acid and importin α/β; (ii) Passive diffusion into the nucleus and 
adsorption via hydrophobic interaction with the benzene ring on the protein surface. According 
to the import mechanism of importin α/β pathway, NBC tags on payload protein presumably bind 
with importin α of importin α/β heterodimer and importin β targets nuclear pore complexes for 
subsequent nuclear translocation of NBC tagged proteins.31 
In summary, we describe the use of aromatic boronic acids (NBC) for synergistic active 
and passive targeting of proteins for delivery to the nucleus. Our mechanistic experiments show 
that the boronic acid mediates active nuclear import, while the benzene ring contributes to 
passive accumulation of proteins into the nucleus. These two moieties can therefore be combined 
or individually used to control protein nuclear targeting. Unlike TPP, which solely relies on 
membrane potential, the NBC tag is a synthetic signal that takes advantage of the intracellular 
transportation machinery for subcellular localization. This finding suggests that transport 
machineries for other subcellular destinations could also be recruited by synthetic tags, paving 
the way for the development of more versatile and efficient intracellular targeting strategies for 
therapeutic and imaging applications. 
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INTRACELLULAR DELIVERY OF LARGE PROTEINS USING NANOPARTICLE-STABILIZED CAPSULES 
7.1 Introduction 
Protein-based therapeutics have widespread applications in biomedical engineering,1 cell 
engineering2, 3 and regenerative medicine.4, 5 An increasing number of proteins, including signaling 
proteins,6 antibodies7, 8 and functional enzymes9, 10 have been preclinically or clinically tested for 
the treatment of diseases. The vast majority of these studies, however, have focused on 
extracellular delivery. 
Intracellular delivery of proteins provides a transient and non-integrative means for the 
regulation of cellular protein functions, and it has recently attracted the interest of researchers 
and clinicians. However, despite significant advances in the development of intracellular protein 
delivery tools major challenges still remain.11 A key aspect that remains unresolved is the rate of 
cytosolic release of the macromolecule in its active form; unlike small molecules, proteins display 
a wide diversity of size and conformations that may inhibit cytosolic access, typically through 
entrapment in the endosomal/lysosomal pathway.12 To address this problem, a number of 
delivery platforms have been developed.13 For instance, endosomal escape agents, cell 
penetrating peptides, and endosomal lysis agents such as chloroquine14 have been effective at 
facilitating protein delivery into cells.15 Nevertheless, the delivery performance of these 
traditional methods is still limited in efficiency,16 in particular for proteins of large size.17, 18  
 Membrane fusion is an alternative approach that conveys rapid release of cargo proteins 
into the cytosol by bypassing endosomal entrapment.19 We have previously developed a 
nanoparticle-stabilized capsule (NPSC) platform for intracellular protein delivery through direct 
membrane fusion20, 21 wherein the terminal functional group on the gold nanoparticles (AuNPs) is 
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a tetrapeptide, His-Lys-Arg-Lys (HKRK). Despite their high efficiency, tight binding of HKRK AuNPs 
to proteins of large size resulted in ineffective payload release into the cytosol. We hypothesized 
that decreasing the overall charge of the terminal group on the AuNPs could reduce their 
interaction with proteins, thereby improving delivery efficiency for larger systems. We used 1-
guanidino-2-(4-imidazole)propionic acid (GIPA, Figure 7.1) as the terminal group of the AuNP 
ligand, providing effective cytosolic delivery of large proteins, including dsRed and β-galactosidase 
(β-gal), into the cytosol. Notably, the synthesis of the GIPA ligand was far more facile than the 
peptide-based ligand.  
 
Figure 7.1. Schematic illustration of a new platform of intracellular protein (dsRed and β-
galactosidase) delivery using GIPA AuNPs-stabilized capsule. 
7.2 Methods 
7.2.1 Preparation of GIPA Ligand 
Synthesis of Compound 1 
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1-(Triphenylmethyl)-L-histidine (1.50 g, 3.77 mmol) was dispersed in 20 mL methanol and mixed 
with triethylamine (382 mg, 0.53 mL, 3.77mmol). The suspension was stirred at room temperature 
for 10 min. Ethyl trifluoroacetate (698 mg, 0.58 mL, 4.91mmol) was added into the white 
suspension dropwise. The suspension turned into clear brownish solution after 1 h stirring at 
room temperature. The stirring was continued for another 5 hrs. Then the pH of the solution was 
adjusted to 1-2 with 1 M HCl at 0 °C. The aqueous solution was extracted with chloroform for 5 
times. The combined organic layer was dried over Na2SO4 and concentrated in vacuo. The white 
solid was dissolved with a minimal amount of methanol and diethyl ether mixture (v/v = 1:1) and 
further recrystallized with n-hexanes at 4 °C. The product was filtered and dried under vacuum as 
white solid (1.55 g, 3.14 mmol, 83.3%) (Compound 1, Figure 7.2). 1H NMR (400 MHz, DMSO-d6): δ 
9.57 (s, 1H), 7.44 – 7.33 (m, 9H), 7.28 (d, J = 1.4 Hz, 1H), 7.10 – 7.00 (m, 6H), 6.66 (d, J = 1.3 Hz, 
1H), 4.48 (s, 1H), 3.03 (dd, J = 14.7, 4.1 Hz, 1H), 2.90 (dd, J = 14.6, 10.3 Hz, 1H). MALDI-MS m/z 
calculated for C27H22F3N3O3 [M + H]+ 493.16, found 493.53. 
 
Figure 7.2. Synthetic scheme of GIPA ligand. 
 
Synthesis of Compound 2 
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Compound 4 (Figure 7.2) was synthesized according to previously reported procedure.22 
Compound 1 (650 mg, 1.32 mmol), Compound 4 (982 mg, 1.58 mmol), and diisopropylamine 
(DIPEA, 511 mg, 0.69 mL, 3.95 mmol) were dissolved in 15 mL dimethylformamide (DMF) and 
stirred for 10 min at 0 °C. 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate (HATU, 601 mg, 1.58 mmol) was dissolved in 3 mL DMF and added into 
the previous mixture dropwise. Then the solution was warmed up to room temperature and 
stirred for 2 hrs. The reaction was quenched with 5 mL deionized water and diluted with 100 mL 
ethyl acetate. The organic layer was washed with 0.1 M HCl for 3 times, saturated NaHCO3 solution 
for 3 times, and saturated NaCl solution for 5 times. Then the organic layer was separated and 
dried over Na2SO4. The mixture was concentrated and purified by column chromatography over 
silica gel with Ethyl acetate and subsequently ethyl acetate–methanol (95:5). The product was 
concentrated in vacuo and obtained as pale yellow oil (1.19 g, 1.08 mmol, 81.8%) (Compound 2, 
Figure 7.2). 1H NMR (400 MHz, CDCl3): δ 8.67 (d, J = 7.0 Hz, 1H), 7.56 (s, 1H), 7.47 – 7.38 (m, 7H), 
7.38 – 7.33 (m, 9H), 7.33 – 7.26 (m, 5H), 7.25 – 7.18 (m, 3H), 7.16 – 7.07 (m, 6H), 4.72 (q, J = 6.0 
Hz, 1H), 3.69 – 3.60 (m, 6H), 3.60 – 3.55 (m, 6H), 3.55 – 3.48 (m, 2H), 3.48 – 3.35 (m, 4H), 3.10 (dd, 
J = 15.0, 4.8 Hz, 1H), 3.02 – 2.94 (m, 1H), 2.14 (t, J = 7.4 Hz, 2H), 1.63 – 1.52 (m, 2H), 1.40 (p, J = 
7.2 Hz, 2H), 1.35 – 1.08 (m, 14H). MALDI-MS m/z calculated for C65H75F3N4O6S [M + Na]+ 1119.54, 
found 1119.63. 
Synthesis of Compound 3 
Compound 2 (1.19 g, 1.08 mmol) was dissolved in 2 mL methanol. LiOH·H2O (228 mg, 5.42 mmol) 
was dissolved in 2 mL deionized water and added into the methanol solution in one portion at 
room temperature. The mixture was stirred for 15 hrs. CHCl3 was used to extract the solution for 
6 times. The combined organic layer was dried over MgSO4 and concentrated in vacuo without 
further purification. The deprotected product (680 mg) was directly used for the next step. The 
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product after deprotection (272 mg, 0.27 mmol), N,N’-di-(tert-butoxycarbonyl)thiourea (Bis-Boc-
thiourea, 63 mg, 0.23 mmol), and DIPEA (0.1 mL, 0.57 mmol) were dissolved in 2 mL 
dichloromethane (DCM) while being flushed with N2. N-Iodosuccinimide (NIS, 51 mg, 0.23 mmol)23 
was dispersed in 2 mL DCM and added into the mixture in one portion at 0°C. The reaction was 
then warmed up to room temperature and stirred for 15 hrs. Na2S2O4 (10 mL 1 M) solution was 
added to quench the reaction and stirred for another 15 min. Afterwards, the mixture was diluted 
with 100 mL ethyl acetate and washed with saturated NaCl solution for 3 times. The organic layer 
was separated and dried over Na2SO4. The mixture was concentrated and purified by column 
chromatography over silica gel with ethyl acetate–methanol (95:5). The product was obtained as 
yellow oil (198 mg, 0.16 mmol, 44.0%) (Compound 3, Figure 7.2). 1H NMR (400 MHz, CDCl3): δ 9.00 
(d, J = 7.2 Hz, 1H), 7.44 (t, J = 1.8 Hz, 2H), 7.43 – 7.40 (m, 3H), 7.34 (td, J = 4.4, 1.8 Hz, 9H), 7.31 (q, 
J = 1.9, 1.5 Hz, 2H), 7.30 – 7.26 (m, 6H), 7.24 (t, J = 1.3 Hz, 1H), 7.22 (d, J = 2.2 Hz, 1H), 7.20 (t, J = 
1.3 Hz, 1H), 7.16 – 7.10 (m, 5H), 3.70 – 3.61 (m, 6H), 3.59 (dq, J = 6.2, 4.0, 2.9 Hz, 5H), 3.51 (t, J = 
5.4 Hz, 2H), 3.45 (t, J = 6.9 Hz, 3H), 2.15 (t, J = 7.3 Hz, 2H), 1.58 (p, J = 6.9 Hz, 3H), 1.52 (s, 7H), 1.46 
(d, J = 1.6 Hz, 8H), 1.39 (q, J = 7.5 Hz, 2H), 1.25 (d, J = 23.0 Hz, 16H). ESI-MS m/z calculated for 
C74H94N6O9S [M + H]+ 1243.7, [M + H + CH3OH]+ 1275.7, found 1243.5, 1275.5. 
Synthesis of GIPA Ligand 
Compound 3 (198 mg, 0.16 mmol) was dissolved in 2 mL anhydrous DCM and stirred at room 
temperature with N2 flushed. A mixture containing 9.25 mL trifluoroacetic acid (TFA), 0.25 mL 1,2-
ethanedithiol (EDT), 0.25 mL triisopropylsilane (TIPS), and 0.25 mL deionized H2O was made and 
added into the DCM solution. The mixture was then stirred at room temperature for 1 hr under 
N2 protection. The solvent was evaporated afterwards and the residue was washed with n-
hexanes for 2 times, n-hexanes–diethyl ether (v/v = 4:1) for 4 times. The residue was dried under 
vacuum and the product was obtained as pale yellow oil (105 mg, 0.13 mmol, 83.1%) (GIPA 
 
125 
Ligand, Figure 7.2). 1H NMR (400 MHz, CDCl3): δ 8.82 – 8.46 (m, 2H), 8.28 (d, J = 63.0 Hz, 2H), 7.38 
(s, 2H), 7.27 (s, 2H), 4.77 (s, 1H), 3.61 (t, J = 13.6 Hz, 16H), 3.43 (p, J = 21.3, 17.8 Hz, 8H), 2.51 (q, J 
= 7.4 Hz, 2H), 1.56 (dp, J = 20.4, 6.6 Hz, 5H), 1.43 – 1.15 (m, 19H). MALDI-MS m/z calculated for 
C26H50N6O5S [M + H]+ 559.36, found 559.50. 
7.2.2 Gold nanoparticle (AuNP) synthesis and functionalization with GIPA Ligand 
The AuNPs (ca. 2 nm core size) were synthesized according to previously reported procedures.24  
The 1-pentanethiol-stablized AuNPs were functionalized with GIPA Ligand via place-exchange 
reactions25.  Briefly, 20 mg AuNP stabilized with 1-pentanethiol was dissolved in 2 mL anhydrous 
DCM and stirred at room temperature with N2 flushed. GIPA Ligand (60 mg) was dissolved in 2 mL 
DCM–methanol mixture (v/v = 9:1) and added into the AuNP solution. The mixture was then 
stirred at room temperature for 96 hrs under N2 protection. The solvent was evaporated 
afterwards and the residue was washed with n-hexanes–DCM (v/v = 9:1) for 5 times. Then the 
functionalized AuNPs were dispersed in Mili-Q water and dialyzed using 10,000 MWCO SnakeSkin 
Dialysis Tubing (Thermo Scientific, USA) for 120 hrs. The concentration of the AuNP solution was 
measured according to a reported method by UV spectroscopy on a Molecular Devices 
SpectraMax M2 at 506 nm.26  Transmission electron microscopy (TEM) of AuNPs was performed 
on a JEOL 2000FX electron microscope (Figure 7.3). Dynamic light scattering (DLS) profiles (Figure 
7.4) and zeta potential were carried out on a Malvern Zetasizer Nano ZS. The surface zeta 
potential of GIPA-AuNPs was (14.6 ± 0.4) mV. 
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Figure 7.3. TEM image of GIPA-functionalized AuNPs. The black scale bar is 20 nm as denoted.  
 
 
Figure 7.4. DLS histogram of GIPA-functionalized AuNPs, demonstrating the hydrodynamic 
diameter distribution of nanoparticles.  
7.2.3 Cell culture 
HeLa cells were cultured in a humidified atmosphere (5% CO2) at 37 °C, and grown in Dulbecco’s 
modified eagle’s  medium  (DMEM, low  glucose) supplemented with  10%  fetal  bovine  serum  
(FBS) and 1% antibiotics (100 U·mL-1 penicillin and 100 μg·mL-1 streptomycin). 
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7.2.4 Fluorescence titration 
In the fluorescent titration experiment between nanoparticles and GFP, the change of 
fluorescence intensity at 515 nm was measured with an excitation wavelength of 485 nm at 
various concentrations of AuNPs from 0 to 200 nM on a Molecular Devices SpectraMax M2 
microplate reader (at 25 °C). Decay of fluorescence intensity arising from 100 nM GFP was 
observed with increasing NP concentration. Nonlinear least-squares curve fitting analysis was 
carried out to estimate the binding constant (Ks).27 The fluorescent titration between 
nanoparticles and dsRed was performed similarly except the excitation wavelength of 561 nm and 
emission wavelength of 585 nm. 
7.2.5 Protein-NPSC complex formation 
To make the protein-NPSC complex, 2.5 μM GIPA AuNPs were incubated with 1.5 μM of protein 
in 60 μL of phosphate buffer (5 mM, pH = 7.4) for 10 min. Then, 1 μL of linoleic acid was mixed 
with 500 μL of phosphate buffer (5 mM, pH = 7.4) containing 1 μM GIPA AuNPs and agitated 
with an amalgamator (Yinya New Materials Co. Ltd, Hangzhou, China) at 5000 rpm for 100 s to 
form emulsions. Finally, the mixture of the protein and GIPA AuNPs were diluted to 135 μL with 
phosphate buffer (5 mM, pH = 7.4) followed by the addition of 15 μL of the emulsion. The protein-
NPSC complexes were ready to use after 10 min of incubation at room temperature. The final 
concentrations of GIPA AuNPs and the protein were 1.5 μM and 600 nM, respectively. 
7.2.6 Protein delivery 
A total of 240,000 HeLa cells were cultured in a confocal dish for 24 hrs prior to delivery. The cells 
were washed with cold phosphate buffer saline (PBS) thrice right before delivery. After 
preparation, the cells were incubated in protein-NPSC complex solution (150 μL of the complex 
diluted by 1.35 mL of the DMEM without FBS) for 1 hr, followed by incubating with fresh DMEM 
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(with 10% FBS) for 10 min, unless otherwise mentioned. The cells were then kept in PBS and 
imaged by a laser scanning confocal microscope (LSM 510, Zeiss, Germany). 
7.2.7 X-gal staining 
Cells were stained according to the assay kit (Genlantis, USA). Briefly, cells were washed with PBS 
once and fixed with the fixation solution followed by 4 hrs of staining. Cells were then washed 
once with PBS and observed under an optical microscope. Experiments were performed in 
triplicate.  
7.3 Results and Discussion 
 The key design parameters for NPSC formation is the presence of a guanidinium group to 
pin the particle to the fatty acid droplet through hydrogen bonding and electrostatic 
interactions.28 The short peptide HKRK on the ligand terminal of our NPSC delivery platform 
contains two lysine residues that increase positive charge density. As strong electrostatic 
interaction may result in inefficient release of proteins with high molecular weight, we truncated 
the structure of HKRK, leaving only imidazole and guanidine groups on the ligand. We synthesized 
the terminal based on a histidine derivative, adding the guanidine group to mimic a peptide 
terminal with reduced charge density (Figure 7.2). The imidazole residue on the histidine 
derivative provides a positive charge equally distributed between two nitrogen atoms at 
physiological pH. Moreover, it facilitates delivery due to a proton sponge function that promotes 
protein release if the payload is entrapped in endosomes.29 The guanidine group interacts with 




GIPA AuNPs were prepared using 2 nm AuNPs (Figures 7.3, 7.4) through a place-exchange 
reaction. From TEM results, there was no obvious difference in the core sizes before and after 
GIPA ligand exchange. The zeta-potential of GIPA AuNPs was measured to determine the surface 
charge. As expected, although these AuNPs are positively charged (zeta potential: 15 ± 1 mV), 
their surface charge density was lower than HKRK AuNPs (zeta potential: 32 ± 1 mV).31 The 
reduced charge density of AuNPs would be expected to weaken the interaction of the NP with 
proteins; fluorescent protein dsRed (a tetramer with a molecular weight of 112 kD)32 was titrated 
with GIPA AuNPs. When AuNPs bind with dsRed, the protein fluorescence is quenched33 due to 
the energy transfer from the photo-excited fluorescent proteins to AuNPs.34, 35 The titration27 
results revealed that the binding constants of AuNPs to dsRed were different (Figure 7.5). The 
binding constant (Ks) of HKRK AuNPs dsRed was (1.9 ± 0.9) × 1010 M-1, whereas the binding 
constant of GIPA AuNPs with dsRed was (1.3 ± 0.4) × 108 M-1.  
 
Figure 7.5. Fluorescence titrations of AuNPs in the presence of fluorescent proteins.  
 
DsRed was likewise an advantageous protein to test the efficacy of GIPA NPSC-based 
protein delivery due to its strong fluorescence and large size. After the formation of dsRed-NPSCs, 
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the overall capsule diameter was 130 ± 55 nm (Figure 7.6), similarly to what we have previously 
reported.20 The NPSCs were diluted with Dulbecco's Modified Eagle Medium for cell culture 
experiments, and after 1 hr incubation, we measured the efficiency of dsRed delivery into cells. 
Flow cytometry results indicated that 65% cells were stained with dsRed (Figure 7.7). The average 
fluorescence intensity was 7 times higher than control groups. In comparison, only 18% cells 
showed uptake of dsRed when delivered with HKRK NPSCs, indicating poor performance of this 
platform delivering proteins of large size. Notably, dsRed was observed evenly distributed 
throughout the cytosol, but not in nucleus (Figure 7.7e). 3D image projections further confirmed 
this cytoplasmic distribution of dsRed (Figure 7.7f). As proteins with molecular weight higher than 
60 kD cannot diffuse passively into the nucleus,36 these results show that dsRed is in its native 
tetramer structure. Together these data demonstrate that GIPA AuNPs are able of efficiently 
delivering large proteins into the cytosol without affecting their structure. 
 





Figure 7.7. Delivery of dsRed to cytosol of HeLa cells. a) Flow cytometry results of dsRed delivery 
by GIPA NPSCs. b) Quantification of average fluorescence intensity of cells. c) Flow cytometry 
results of dsRed delivery by HKRK NPSCs. d) Quantification indicates GIPA NPSC has much higher 
efficiency for the delivery of dsRed. e) LSCM image showing dsRed delivery into HeLa cells by 
GIPA NPSCs. f) Z-stack image of dsRed delivery. Scale bars: 20 µm. 
 
Delivery of enzymes into cells is a promising strategy for enzyme replacement and 
prodrug activation therapies. While we have demonstrated that caspase-3, an apoptotic enzyme 
of small size, can be rapidly delivered into the cytosol using a NPSC platform,20 the creation of 
delivery platform for enzymes of higher molecular weight would greatly expand the utility of this 
strategy. Rapid delivery of β-gal to the cytosol is a promising approach for efficient prodrug 
activation therapy in cancer cells,37, 38 yet the large size of this enzyme (464 kD) in its tetrameric 
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form is an obstacle for cytosolic access.18 We assessed whether the GIPA NPSC platform was 
capable of efficiently delivering β-gal into the cytosol in HeLa. The size of β-gal-GIPA NPSCs is 110 
± 50 nm when measured by dynamic light scattering (DLS; Figure 7.8). Delivery of fluorescein 
isothiocyanate labeled β-gal (FITC-β-gal) revealed the cytosolic but not nuclear distribution of the 
protein after 1 hr delivery (Figure 7.9a), similar to that of dsRed. Due to its large size, β-gal cannot 
passively diffuse into nucleus. By delivering FITC-β-gal we were able to confirm that GIPA NPSCs 
efficiently deliver β-gal specifically into the cytosol. X-gal staining was then used to demonstrate 
retention of enzymatic activity of delivered β-gal. After delivery, the media was removed and cells 
were stained with X-gal for 4 hr. Notably, β-gal bound to GIPA NPSCs, but not β-gal alone, was 
efficiently delivered to the cell (Figure 7.9 b-d). Thus, GIPA NPSC platforms are capable of 
delivering functional enzymes of large size into cells without hampering their structure or 
function. 
 






Figure 7.9. Distribution of β-gal in HeLa cells after delivery. a) LSCM image showing FITC- β-gal 
delivery. Scale bar: 10 µm. b) X-gal staining of delivered β-gal in HeLa cells. c) X-gal staining of 
cells incubated with free β-gal alone. d) X-gal staining of cells incubated with NPSCs alone. Scale 
bars: 100 µm. 
7.4 Conclusion 
 In summary, we have developed an effective intracellular delivery strategy for proteins of 
high molecular weight using GIPA AuNPs stabilized capsules. GIPA AuNPs interact weakly with 
proteins and rapidly deliver the payload into the cytosol via a protein-GIPA NPSC complex. Both 
dsRed and β-galactosidase are effectively transduced into cells without hampering their native 
structures and functions. These studies demonstrate the use of supramolecular chemistry to tune 
the interaction between ligands of nanoparticles and proteins, providing a strategy for optimizing 
nanomaterial delivery vehicles.  
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